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The following abbreviations have been used. Most have also been defined in
the text.
AAG a!-acid glycoprotein (orosomucoid)
AET 2-aminoethylisothiouronium bromide hydrobromide
APC antigen-presenting cell(s)
aLA a-lactalbumin
BSA bovine serum albumin
|3LG P-lactoglobulin
CBMC cord blood mononuclear cell(s)
CI confidence interval
cpm counts per minute
CTAB cetyltrimethylammonium bromide (cetavlon)
DEAE diethylaminoethyl-
ELISA enzyme-linked immunosorbant assay
FS forward scatter
HPLC high-performance liquid chromatography
hsp heat-shock protein






LDA limiting dilution analysis
LPL lamina propria lymphocyte
NK natural killer
PAS periodic acid Schiff s reagent




PPD purified protein derivative of M. tuberculosis (tuberculin)
PWM pokeweed mitogen
SDS-PAGE sodium dodecyl-sulphate polyacrylamide gel electrophoresis
SEC/MALLS size-exclusion chromatography/multi-angle laser light scattering
SI stimulation index
SK or SK/SD streptokinase/streptodornase
SRBC sheep red blood cell(s)
SS side scatter
rpm revolutions per minute
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Abstract
Saccharomyces cerevisiae (bakers'/brewers' yeast) is a ubiquitous dietary constituent
in the developed world. Previous studies, using semi-quantitative ELISA techniques,
suggested that patients with Crohn's disease have higher titres of IgG and IgA isotype-
specific antibodies to this yeast than are found in normal control subjects or patients with
ulcerative colitis. For this study, in order to allow more stringent assay standardisation and
more meaningful numerical comparison of the relative antigen-binding capacities of different
sera, a quantitative ELISA was developed for measurement of anti-yeast antibodies, using a
soluble extract of yeast (sacc) as the antigen. The finding of raised levels of yeast antibodies
in Crohn's disease was confirmed, and the data suggest that this may be related to the
presence of disease in the small bowel, although this latter observation did not reach
statistical significance. Patients with chronic liver disease also had higher antibody levels than
controls, but less markedly so than in Crohn's disease. When sera were tested in a similar
assay for antibodies to bovine casein, no difference was found between controls and the
Crohn's or liver disease group.
The response of peripheral blood mononuclear cells (PBMC) to sacc was examined
using a proliferation assay measuring uptake of tritiated thymidine. Cells from normal
controls demonstrated dose-dependent proliferation, the time-course of which resembled that
obtained with known recall antigens. Following separation of cell populations by rosetting
with sheep erythrocytes, the responding cells were shown to be T-lymphocytes and the
magnitude of the response was sensitive to the number of antigen-presenting cells present in
the culture. When positive selection with immunomagnetic beads was used to further separate
T-cells into highly purified CD4+ and CD8+ populations, responsiveness to yeast co-separated
with the CD4+ subset. Following negative selection of cells expressing CD45RO or CD45RA,
responsiveness was largely, but not exclusively, confined to the CD45RO+ population.
Limiting dilution analysis of peripheral blood T-cells gave estimates of the sacc-specific
precursor cell frequency in keeping with values previously reported for recall antigens,
although the experimental data could not be shown to conform to single-hit kinetics. By
sequential stimulation in long term culture, it was possible to obtain populations of cells
which were uniquely responsive to sacc but unresponsive to other recall antigens. At some
concentrations of sacc, proliferation responses of PBMC from Crohn's disease patients were
higher than those in normal subjects, but the difference was not convincing overall.
Digestion of sacc with pronase abolished the T-cell response but left specific
antibody-binding intact, supporting the suggestion that antibody recognition is dependent on
carbohydrate epitopes. Yeast cell wall mannan is implicated as the likely site of B-cell
epitopes; evidence pertaining to T-cell epitopes is less conclusive.
Thus, this study provides evidence that immune sensitisation to a common dietary
constituent frequently occurs in the normal population, leading to detectable humoral and
cellular immune responses. The T-cell response appears to be genuinely antigen-specific, and
not due to non-specific lymphocyte activation. The gastrointestinal lymphoid system may be
the site at which primary sensitisation occurs. In patients with Crohn's disease, the humoral




Background: S. cerevisiae and Crohn's disease
In 1988, Main et alusing a boiled suspension of Saccharomyces cerevisiae
(bakers'/brewers' yeast) as antigenic substrate in an ELISA, reported specific
antibodies of IgG and IgA isotype in patients with Crohn's disease, which
distinguished them from both normal subjects and those with ulcerative colitis.
Subsequently, it was shown that this observation held true for specific IgG against 11
out of 12 different strains of this yeast, whereas there was no difference between
groups for antibodies to Candida albicans} However, there was considerable variation
between patients with respect to their relative antibody response to different S.
cerevisiae strains, and strain-specific antigenic heterogeneity was subsequently
demonstrated by ELISA inhibition studies.3 Interestingly, the strain against which
Crohn's disease patients had not demonstrated increased antibodies appeared to be
antigenically more related to C. albicans than other S. cerevisiae strains.
Barnes et al4 also found IgG anti-5. cerevisiae in a larger proportion (63%)
of Crohn's disease patients than in normal controls (8%), ulcerative colitis (15%),
coeliac disease (15%), dermatitis herpetiformis (10%), irritable bowel syndrome
(20%) and atopic eczema (16%). Furthermore, IgA 300-5. cerevisiae was present in
43% of the Crohn's disease group but in only 1 of 60 normal controls and in none
of the other disease groups. In contrast, the prevalence of IgG antibodies to E. coli
was increased equally in Crohn's disease and ulcerative colitis, whereas IgG
antibodies to cow's milk were detected with increased frequency in ulcerative colitis
but not Crohn's disease, and IgG antibodies to gliadin and ovalbumin were no more
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frequent than normal in either of the inflammatory bowel diseases.
In a study of twins who were concordant or discordant for Crohn's disease or
ulcerative colitis, Lindberg et al.5 measured IgG, IgA and IgM isotype-specific
antibodies to extract of whole S. cerevisiae as well as a commercial preparation of
mannan from S. cerevisiae, ovalbumin, bovine P-lactoglobulin and gliadin. Compared
with matched controls, twins with Crohn's disease had significantly elevated
antibodies of all three isotypes against mannan, and of IgA against whole yeast
extract, in the presence of normal or decreased antibodies to the other dietary
antigens; IgG to yeast extract was higher in those with disease exclusively affecting
the small bowel than in those with large bowel disease (with or without small bowel
disease). Healthy twins of those with Crohn's disease also had elevated IgA against
mannan and yeast extract, but this was less marked than in those with disease. Among
twins with ulcerative colitis, there was a modest elevation of IgA against mannan and
gliadin, but this was slightly less than in their healthy twins. Only two of the subjects
in this study (both of whom had Crohn's disease) were said to have had active
disease.
Giaffer et al.6 compared IgG and IgA antibodies to three S. cerevisiae strains
in Crohn's disease, ulcerative colitis and coeliac disease. Specific IgG to all three
strains was raised in both Crohn's disease and coeliac disease, whereas specific IgA
to all three strains was raised in Crohn's disease only. Crohn's disease subjects with
small bowel disease (with or without large bowel disease)0 had higher levels of IgG
to two yeast strains, and IgA to one strain, than those with exclusively large bowel




These studies continued an established theme of investigating the possibility
of abnormal immune responsiveness to dietary antigens in gastrointestinal disease.
However, in addition, they introduced S. cerevisiae as a novel potential antigen —
so far as can be ascertained, the existence and nature of the normal human immune
response to this organism has not previously been investigated.
This study, therefore, represents an attempt not only to expand on previous
work on bakers' yeast in the context of inflammatory bowel disease, but also to
describe the immune response in normal subjects, with particular reference to cellular
immunity and antigen-specificity, and to formulate and test hypotheses concerning the
nature of the antigenic substrate(s) involved.
In the remainder of this section, material will be introduced which is of wider
historical or technical relevance to the data which are then presented. The latter will
then be discussed in the context of this, and other, information.
Foods as antigens
Circulating antibodies to dietary antigens
Historically, the impetus for investigating the humoral response to dietary
antigens has been two-fold: firstly, there has been a need to arrive at a
phenomenological description of normal immunity from which basic mechanisms
might be deduced; secondly, there has been considerable interest in examining how
such responses may be modified by different disease states, thus providing insight
into aetiopathology, or information useful in diagnosis or management of patients.
Naturally, much of the research in this area has been ultimately concerned
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with pathological conditions which are overtly associated with adverse clinical
reactions to dietary components, food allergy per se being the most obvious example.
In this context, the biological significance of antigen-specific IgE as a cause of type 1
(immediate, anaphylactic) hypersensitivity reactions is well-established, and will not
be discussed further. However, in the course of these investigations, many
observations have been made on the development of antibody responses in normal
subjects and in those with a variety of pathologies.
Observations in normal subjects
"Circulating antibodies to ingested proteins can be detected so
commonly that their presence must be considered a natural occurrence. "
Because of its nutritional importance, well-characterised protein composition and
frequent association with gastrointestinal intolerance, the overwhelming majority of
studies of antibodies to dietary antigens have been concerned with those specific for
cow's milk antigens.
In 1965, Rothberg and Farr,8 using a radioimmunoassay developed by the
latter, carried out a quantitative examination of circulating antibodies to bovine serum
albumin (BSA) and a-lactalbumin (aLA), in a large sample of nine hundred children
and adults, comprising both normal subjects and those suffering from a range of
unrelated conditions. The most striking finding related to the way in which the
prevalence of antibodies of either specificity depended on the age of the subjects at
the time of testing: up to 3 months of age, anti-BSA was present in about 1/3 of
infants, the same prevalence as in adults of reproductive age (16-40 years), and
therefore in keeping with transplacental, passive acquisition; thereafter, prevalence of
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anti-BSA increased to 61% between the ages of 6 and 15 years, and then declined to
<10% over the age of 40 years. Furthermore, when the antigen-binding capacity of
positive sera was quantified, all of those with a high binding capacity were from
children. Compared with healthy subjects, prevalence of anti-BSA was increased
among children with iron deficiency anaemia (who were also drinking large amounts
of milk) and among adults with allergic diseases, including asthma, presumed to be
unrelated to milk. Although the prevalence of anti-BSA was not increased among
adults with gastrointestinal disease, positive sera from this group had the highest
antigen-binding capacity of any of the adult groups. Antibodies to aLA showed a
similar age distribution to, but were about half as prevalent as, anti-BSA.
Subsequently, Korenblat et al.9 investigated possible reasons for the age-
dependent decline in anti-BSA. Neither re-establishing childhood patterns of oral
intake of BSA, nor parenteral immunisation with the antigen, could induce an
antibody response in adult subjects who had become seronegative, although titres
increased among those who had continued to produce antibody. Therefore, it was
inferred that non-production of anti-BSA by adults was due to a state of acquired
immunological unresponsiveness rather than relative lack of exposure to, or altered
gut handling of, antigen.
These findings have been confirmed and extended by other studies, some of
which have also examined the effect of delayed antigen exposure on the development
of antibody responses. For example, Kletter et al.,1'10 using radio-immunodiffusion
and haemagglutination, demonstrated milk-specific IgG and IgA which rose to a peak
within the first few months and began to decline after the first year in infants subject
to early exposure to cow's milk. Exclusive breast-feeding delayed the rate of rise of
8.
these antibodies and reduced the peak and final levels achieved at one year, in some
cases completely abolishing the response. This effect of breast-feeding on the
appearance ofcirculating antibodies has been confirmed by others using more modern
ELISA techniques,11'12 and has been observed to be paralleled by a similar effect on
numbers of circulating cells secreting milk-specific IgA.13 Furthermore, feeding with
a hydrolysed formula containing casein peptides, and therefore presumed to be non-
immunogenic, appears to have a similar effect to breast-feeding.14 However, one study
could only demonstrate such a delay for the appearance of specific IgG (but not IgA
or IgM),15 and another, which only investigated IgA and IgM, found no effect.16
Recently, there has been considerable interest in investigating the IgG subclass
distribution of antibodies to dietary antigens, since it had been suggested that
antibodies of the IgG4 isotype might be related to food allergy (reviewed by
Barnes17). However, Husby et a/.,18 in an investigation of antibodies to milk proteins
(by rocket radio-immunoelectrophoresis) in healthy adults, found that all IgG
subclasses, with the exception of IgG3, were represented (although Barnes et al.19 did
find IgG3 to milk, by ELISA, in 53% of normal adult sera), and that specific IgG4
could often be detected even when total serum IgG4 was low. Furthermore,
Kruszewski et al,20 demonstrated specific IgG4 against food allergens in 92% of
normal blood donors, and Roger et al.21 found that its presence in ovalbumin-sensitive
children correlated poorly with specific IgE, and was a poorer predictor of a positive
oral provocation test. There would, therefore, appear to be little doubt that antibodies
of the IgG4 subclass are part of the normal repertoire of antibodies to dietary antigens.
Notwithstanding this, the observation that antibodies to dietary antigens do not decline
with age in the usual way in subjects with apparently non-diet-related allergic
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conditions, has repeatedly been made.19'22
In summary, the development and later decline of circulating antibodies to
dietary antigens appears to be an integral part of the ontogeny of the normal humoral
immune response. The antibody response to specific proteins is partly determined by
age of first exposure. Antibodies of all isotypes can be produced, but among the IgG
subclasses, there is no consensus on whether special significance can be attached to
any particular response profile.
Observations in different disease states
Diabetes. Following a reported association between early exposure to cow's milk and
the onset of childhood insulin-dependent diabetes (IDDM), the possible role of an
aberrant immune response to milk proteins has been investigated.
In a large and comprehensive study in Finnish diabetic children, Virtanen et
al.23 measured IgG and IgA antibodies, by ELISA, to cows' milk formula, BSA and
P-lactoglobulin (PLG). Using multivariate analysis, IgA to milk formula was shown
to be an independent risk factor for IDDM among both diabetic-sibling control and
diabetic-population control pairs, when infant feeding patterns (duration of breast¬
feeding and age at exposure to cow's milk) and current milk consumption were taken
into account. Among diabetic-sibling control pairs, it was also independent of the
presence of islet cell antibodies. Similar results were obtained from a Swedish study,
although this suggested that antibodies specifically directed against PLG were an
independent risk factor.24
Other researchers have approached this problem using a newer technique for
measuring specific antibodies — particle-concentration fluoroimmunoassay (PCFIA).
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Karjalainen et al.25 found that this could detect IgG anti-BSA among newly diagnosed
diabetics with 100% sensitivity and 98% specificity, and that this subset of antibodies
was not demonstrable by standard ELISA, whereas both techniques could detect
increased IgA anti-BSA in diabetics. These findings were extended when it was
shown that a large amount of the anti-BSA activity in diabetics was inhibitable by
ABBOS, a 17-mer peptide having cross-reactivity with a 69 kD P-islet cell surface
protein, p69.26 These antibodies appeared to return to normal within 2 years of
diagnosis, after which most of the remaining anti-BSA was not inhibitable by
ABBOS. These results were supported by a French study which detected IgG anti-
BSA by PCFIA in new diabetics with a disease sensitivity of 74.4% and specificity
of 95%, compared with 83.7% and 98%, respectively, for islet cell antibodies.27
Coeliac disease. Coeliac disease (gluten-sensitive enteropathy) is the paradigmatic
example of immunologically mediated enteropathy,28 and, as such, it will be discussed
in greater detail elsewhere. It is characterised by the presence of at least two classes
of circulating antibodies (particularly, of IgA isotype): i) antibodies specific for
alcohol-extractable components of wheat gluten — anti-gliadin antibodies (AGA),29
and ii) autoantibodies to a component, or components, of connective tissue, classified
as anti-[R, reticulin], anti-endomysial (AEA) and anti-jejunal antibodies. The latter
three may well be identical, although this has not been proven, but they are not the
same as AGA, since, unlike AGA, their activity is unaffected by absorption with
gliadin.30 Moreover, AEA are more disease-specific, and therefore have a higher
positive predictive value, than AGA.31-33 However, although AGA and AEA do not
appear to be cross-reactive, explants of small intestinal mucosa have been shown to
produce AEA on stimulation with gliadin,34 and it is possible that this is due to
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sharing of T-cell epitopes between antigens with distinct B-cell epitopes. Finally, it
should be noted that none of these antibodies are likely to be pathogenic, since
subjects with selective IgA deficiency are at increased risk of developing coeliac
disease.35
Notwithstanding the special significance ofAGA, patients with coeliac disease
have been demonstrated to have increased antibodies to other dietary antigens. For
example, Taylor et a/.36'37 found highly significant increases in haemagglutinating
antibodies to casein, aLA and PLG (as well as gluten fraction III — a water-soluble
peptic/tryptic digest of gluten) in coeliacs, who differed from the normal controls
more markedly than any of the other disease groups examined. Although these
authors could not detect precipitating antibodies, these were demonstrated by
Ferguson and Carswell,38 who found an increased prevalence of serum precipitins to
wheat, gluten, oats, milk, bovine and sheep serum, and egg yolk (but not rice,
cornflour or egg white) in coeliac children; concomitantly, only gluten-specific
precipitins were present in intestinal secretions. Similarly, Kenrick and Walker-
Smith39 demonstrated precipitating antibodies to at least one of a range of dietary
antigens in 50% of coeliacs and none of the control group, with statistically
significant results for soluble wheat extract (though, interestingly, not gliadin per se),
whole cow's milk and whole bovine serum. Davidson et al.40 found antibodies to
maize, by indirect immunofluorescence, in 44% of coeliac patients, and, unlike wheat
antibodies (detected in 68% on normal diet and 43% on gluten-free diet), their
prevalence was not lower among those on a gluten-free diet. Using ELISA, Scott et
al4] showed that antibodies to casein, aLA, (3LG and ovalbumin were raised in
untreated coeliac disease and found that they did revert to normal on a gluten-free
12.
diet. Barnes and Lewis-Jones42 reported a rather complex profile of antibodies in
patients with dermatitis herpetiformis, in that IgG against gliadin, milk and
ovalbumin, and IgA against milk could be detected irrespective of dietary exclusion
of gluten, whereas IgA anti-gliadin was only found in patients not on a gluten-free
diet.
Thus, since the causal role of dietary gluten in the pathogenesis of coeliac
disease (in the presence of an appropriate immunogenetic background) is fully
established, AGA can be considered to represent a special case of disease-associated
antibodies to a specific dietary antigen. Although antibodies to dietary antigens
unrelated to gliadin are no longer considered to be of diagnostic utility in coeliac
disease,43 they are frequently secondarily elevated, perhaps as a consequence of the
increased mucosal permeability associated with the disease.44-46
Liver disease. Triger et al.41 using particle agglutination assays, found only
equivocal evidence for raised antibodies to dietary proteins (ovalbumin, aLA, PLG
and gluten fraction III) in liver disease, although there were convincing increases in
antibodies to bowel commensal organisms (E. coli and bacteroides spp.) in the same
patients, whether they were suffering from acute hepatitis, chronic active hepatitis or
cirrhosis. However, Andre et a/.,48 using the same technique, did find raised
antibodies to these antigens, and to BSA, in alcoholic cirrhotics; furthermore, the
antibody levels were higher among the 50% of patients in whom circulating immune
complexes could be detected post-prandially. Subsequently, Tamura et al4'' found
increased haemagglutinating antibodies to BSA in adults with liver disease (especially
chronic active hepatitis and cirrhosis), while Lerner et al.,50 by ELISA, reported
antibodies to cow's milk proteins (especially, IgA anti-casein and IgG anti-BSA) in
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children with various liver pathologies. Recently, Aitola et al.,5] in a study of patients
with ulcerative colitis, showed that IgA anti-casein, by ELISA, was higher in subjects
who also had abnormal liver histology, and correlated positively with serum
y-glutamyltransferase and alanine aminotransferase.
One possible mechanism for these phenomena is that there is an enhanced
systemic immune response to dietary proteins secondary to impaired hepatic clearance
of antigenic material absorbed by the gut.50
Inflammatory bowel disease. In 1961, Taylor and Truelove52 reported increased
antibodies to casein and PLG (but not aLA or ovalbumin) in patients with ulcerative
colitis. These were detectable by haemagglutination but not Ouchterlony double
diffusion. None of the antibody titres correlated with age, sex, maintenance of a milk-
free diet, extent or activity of disease, or steroid therapy, but anti-casein was
positively correlated with the chronicity of disease. In an extension of this study,37
they showed that antibodies to gluten fraction III were also raised in ulcerative colitis,
whereas patients with Crohn's disease had either normal or markedly reduced
antibody titres to the same panel of antigens. However, when Jewell and Truelove53
re-addressed this issue a decade later, using a modified haemagglutination technique,
they failed to find raised antibodies in inflammatory bowel disease, although they
were elevated in coeliac disease. Falchuk and Isselbacher54 used the Farr assay to
measure antibodies to BSA, and found them to be present in 86% of Crohn's disease
patients, 57% of those with ulcerative colitis and 43% of normal subjects (as well as
five out of five with untreated coeliac disease), the increased incidence in disease
being due to the presence of high titre antibodies. Furthermore, in the inflammatory
bowel disease patients, high titres were more frequently associated with moderate to
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severe, rather than mild, disease. These authors reported no difference in titres
according to the site affected by Crohn's disease (however, the number of patients
with only large bowel disease was very small). Using indirect immunofluorescence,
Davidson et alw found antibodies to maize and wheat in 33% and 58%, respectively,
of Crohn's disease patients, 50% and 50% of those with ulcerative colitis, compared
with 14% and 12% of normal individuals. Using an isotype-specific solid phase
radioimmunoassay (a precursor of ELISA), Paganelli et al.55 demonstrated increased
levels of IgG and IgM (but not IgA) anti-pLG in both Crohn's disease and ulcerative
colitis. In the Crohn's group, specific IgG was higher in the presence of small bowel
disease and in those with active disease, as determined clinically or by laboratory
indices of inflammation, whereas specific IgM was higher in those with normal
laboratory indices. Specific IgG was also higher in untreated Crohn's patients,
although there was no correlation with duration of symptoms or time since diagnosis
or presentation. Knoflach et al56 measured isotype-specific antibodies to five cow's
milk proteins (a-casein, PLG-A and -B, aLA and BSA) by ELISA — IgM to all five
was raised in both ulcerative colitis and Crohn's disease, IgG to all five in ulcerative
colitis, IgG anti-casein in Crohn's disease, and IgA anti-PLG in ulcerative colitis and
Crohn's disease. In the Crohn's disease group, there was significant correlation
between serum aracid glycoprotein (orosomucoid, AAG) and IgG anti-casein, IgA
anti-casein and IgA anti-BSA. By contrast, in a very similar study in chidren and
young adults, Lerner et al.51 found raised IgG to PLG-A, PLG-B and BSA (but not
aLA or casein) in Crohn's disease (but not ulcerative colitis), raised IgA anti-casein
in both Crohn's disease and ulcerative colitis, and no significant changes for specific
IgM. In this study, IgG anti-BSA was higher in those with more active Crohn's
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disease, but there was no correlation with treatment, duration or site of disease, and
no difference between sexes. Recently, Song et al.5S reported increases in antibodies
to bacterial and food antigens in Crohn's disease and ulcerative colitis, but with a
predilection for Crohn's disease.
As with coeliac disease, it is possible to hypothesise that increased
permeability of the gut mucosa to macromolecules may underlie observations of an
enhanced systemic humoral immune response to dietary antigens in inflammatory
bowel disease. It may also be of relevance that permeability changes are more readily
detected in Crohn's disease, and appear to be more marked in active disease.44'59,60
Other conditions. Other clinical circumstances which have been reported to be
associated with the presence of antibodies to dietary antigens include oral
ulceration,37'61 sickle cell anaemia,62 cystic fibrosis,63 Down's syndrome,64 rheumatoid
arthritis65 and IgA nephropathy;66 in the latter, increased intestinal permeability was
also demonstrated.
One of the more interesting associations is with selective IgA deficiency. This
is the commonest of the humoral immunodeficiency syndromes, with a prevalence in
the U.K. of ~1 in 700. Although the majority of cases are thought to be clinically
silent, the incidence of autoimmune disease (including coeliac disease and connective
tissue diseases) and allergy is increased in this population.67 Buckley and Dees68 found
precipitating antibodies to cow's milk in 18 of 24 subjects with IgA deficiency,
compared with 2 of 65 normal control subjects; the IgA-deficient group also had
higher titres of haemagglutinating antibodies. Huntley et al69 went on to provide
evidence that these precipitins were primarily directed against bovine IgM, and were
cross-reactive with IgM from a variety of ruminant species (goat, sheep, deer and
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elk). Cunningham-Rundles et al.70 showed that the presence of milk-specific IgG,
detected by ELISA, in IgA-deficient subjects, correlated with the presence of
precipitating antibodies and the appearance of circulating immune complexes after
drinking milk. These observations are in keeping with the view that, under normal
circumstances, secretory IgA may have a role in attenuating the systemic
immunogenicity of dietary antigens.
Cellular responses to dietary antigens
Historically, the study of in vitro cellular responses to food-derived proteins
has received less attention than that of specific antibodies. However, more widespread
adoption of techniques in cellular immunology has lead to a change in emphasis in
recent years. Again, much of the data which are available have been derived from
work done in the context of clinical conditions putatively related to food
hypersensitivity.
Food allergy. Borrone et al7X were the first to report enhanced cellular responses to
a dietary antigen in this context. They found positive responses to milk protein in 10
of 21 children with chronic diarrhoea associated with milk consumption and in 3 of
3 with "milk allergy" (which they did not define). May et al.12 examined cellular
responses to milk protein, ovalbumin, wheat and soy in patients with type I
hypersensitivity reactions to foods; although their results were somewhat equivocal,
they did show that positive responses were possible in asymptomatic control subjects,
whose cells gave mean stimulation indices (Sis) of 1.94 and 3.44 to soy and milk,
respectively. Scheinmann et al,73 obtained positive responses to aLA and/or PLG in
37.8% of subjects with immediate or delayed symptoms associated with milk
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consumption (these groups were incompletely differentiated in this study), and in
9.3% of healthy subjects, and also found that the prevalence of a positive response
was higher in those in whom the onset of symptoms had been in the first month of
life. More recently, Eigenmann et al74 reported that lymphocyte responses to milk
proteins in children with milk allergy were no different from those of normal
controls, although the response to a hydrolysed formula feed was lower.
Van Sickle et al.75 specifically investigated patients with milk and soy protein-
induced enterocolitis and correlated the results of antigen-specific lymphocyte
stimulation assays with oral challenge tests. They found geometric mean Sis of <2.2
to all antigens when the oral challenge test was negative; when the relevant oral
challenge test was positive, the geometric mean SI was 8.5 to soy, and 6.0 to casein
(Sis to whey protein were lower at 3.3). These investigators considered an SI of 3.6
to be the upper limit of normal for asymptomatic subjects.
Kondo et al.76 working on the basis that atopic dermatitis (eczema)
macroscopically and histologically resembles a cell-mediated (type IV
hypersensitivity), rather than antibody-mediated, immune response, investigated the
proliferative response of peripheral blood mononuclear cells (PBMC) to BSA and
ovalbumin in chidren with this condition who had delayed onset cutaneous symptoms
following ingestion of milk or egg. They found mean maximal stimulation indices of
>3 to the relevant antigen in eczema, compared with <1.5 in normal controls and
chidren with immediate hypersensitivity (urticaria/angioedema) to milk or egg, the
difference being highly statistically significant. The prevalence of positive antigen-
specific IgE (RAST score >1) in the eczema group was less than half that in the
immediate hypersensitivity group; furthermore, there was no correlation between
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RAST score and the lymphocyte stimulation index. These investigators went on to
show that the proliferating cells were CD4+ T-cells, and that antigen-presenting cells
were necessary for the response. Furthermore, following an elimination diet,
symptomatic improvement was accompanied by a decrease in the cellular response
which was specific for the excluded antigen. This group has also examined the
cytokine secretion profile of cells proliferating in response to ovalbumin. Proliferation
in egg-sensitive eczema was accompanied by production of IL-2 and IFNy, and the
latter distinguished patients from normal controls and those with immediate
hypersensitivity. In all patients, there was inverse correlation between IFNy and IgE
production, and positive correlation between IL-4 and IgE.77-83 The conclusion of
these authors was that food-sensitive eczema is associated with an antigen-specific T-
cell response resembling the pro-inflammatory Th, phenotype, in contrast to the Th2-
like response of T-cells which give rise to type I hypersensitivity. A Th2-like cytokine
profile of ovalbumin-specific T-cells isolated from egg-allergic individuals with
eczema and antigen-specific IgE has recently been described by Katsuki et alM
In the hands of these researchers, the ability of the lymphocyte stimulation
assay to differentiate subjects with immediate from those with delayed
hypersensitivity is impressive. Although the virtual unresponsiveness of cells from
normal control subjects is unusual in the context of other studies on dietary antigens
cited in this section, a similar pattern has been described for cellular responses to
Dermatophagoidespteronyssinus (house-dust mite) allergen, i.e. negligible stimulation
of cells from normal donors and maximal responses in the presence of atopic
dermatitis.85 If reproducible, these results demonstrate the importance of the accurate
classification of subject groups according to clinical criteria, since they imply that T-
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cell responses may depend qualitatively and quantitatively on the precise clinical
manifestations of different hypersensitivity syndromes related to atopy. There is one
report which suggests that responding T-cells in milk-induced eczema express a skin-
specific homing receptor — cutaneous lymphocyte antigen (CLA)86 — and it is
possible that lymphocyte subsets which preferentially home to different anatomical
sites are unequally represented in peripheral blood.
Type I hypersensitivity to nuts is a clinically significant cause of anaphylaxis,
and peanuts are currently the major cause of fatal attacks due to food in the U.K.
(R.S.H. Pumphrey, personal communication). Two groups have recently isolated
peanut-specific CD4+ T-cell clones from allergic patients and shown that these
preferentially produce Th2 cytokines. Higgins et al.si found positive proliferative
responses to peanut, hazelnut and Brazil nut in allergic patients and normal controls
(Sis were markedly higher than those obtained in the studies discussed above), with
a tendency to higher responses in the allergic group; this difference was statistically
significant in the study of de Jong et a/.88 Dorion and Leung89 have claimed that,
following antigen-specific stimulation of cells from peanut-allergic subjects, there is
expansion of T-cells with receptors incorporating the V(32 variable region.
Diabetes. Data on cellular responses to milk-derived proteins in diabetes are
conflicting and differ along the same lines as the antibody data which have been
discussed — one group of workers has found T-cell responsiveness to the BSA-
derived ABBOS peptide in 28 of 31 children with newly-diagnosed IDDM but not
in controls,90 whereas another group found positive responses to [JLG (but not BSA
or casein) in 55% of IDDM compared with 22% of controls.91
Coeliac disease. Although the exact mechanism by which the gastrointestinal lesion
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of coeliac disease is generated is not yet known, there is a great deal of evidence to
suggest that gliadin-specific T-cells are instrumental in the disease process.
Coeliac disease is very strongly associated with the presence of a particular
MHC class II heterodimer, DQ2, encoded by the alleles DQA1*0501 and
DQB 1*0201 in either cis or trans position,92 and the peptide motifs necessary for
binding to this molecule are known.93 96 The same association with DQ2 is also
present in patients with dermatitis herpetiformis.97 Gliadin-specific CD4+ T-cells
isolated from the intestinal mucosa of patients with coeliac disease have been found
to be preferentially restricted by DQ2,98 and parallel observations have been made for
the subset of coeliac disease patients in whom the disease-associated class II molecule
is DQ8, encoded by DQA1*0301/DQB1*0302." Furthermore, a DQ2-restricted,
peripheral blood-derived T-cell clone from a coeliac patient was found to recognise
a peptide comprising residues 31-47 of a-gliadin,100 which has also been shown to
be toxic in vivo.m However, the restriction elements for blood-derived T-cells
responding to gliadin are more diverse than for mucosa-derived cells102'103 — indeed,
one group found only DR-restricted cells in blood from a patient and a normal subject
(interestingly, the peptides being recognised were not those thought to be associated
with disease).104
Gluten-specific T-cells, whether from blood or mucosa, or from healthy or
coeliac subjects, and regardless of restriction element, consistently appear to produce
IFNy on antigenic stimulation, and have been classified as Th0 or Tl^ cells.105'106 They
are able to mediate enterocyte damage in vitro, an action which is mimicked by IFNy
and can be blocked by anti-IFNy.107 IFNy mRNA (by in situ hybridisation) has been
found to be increased in the gut mucosa in untreated coeliac disease, compared with
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coeliacs on a gluten-free diet and normal subjects.108 In view of the detailed
information available on the importance of T-cell sensitisation to gluten in coeliac
disease, the relatively low Sis (mean of ~2, c.f. 1 in controls) to gluten, reported by
Sikora et al.,m are disappointing.
Although gluten-specificity of intra-epithelial lymphocytes (IELs) has not been
established, the number of these cells is increased in coeliac disease, and the view is
emerging that they may be the ultimate mediators of mucosal damage, possibly driven
by cytokine(s) released by antigen-specific lamina propria lymphocytes (LPLs).110
This view is supported by the high granzyme B content of IELs in coeliac disease,
compared with normal subjects and those with giardiasis.111 Differential expression
of activation and proliferation markers on IELs and LPLs has been described,112'113
and it is possible that cytotoxic IELs proliferate in response to non-proliferative
activation of LPLs.114 A high proportion of IELs express y8 T-cell receptors, and
increased numbers of circulating y5 cells have been reported in children with coeliac
disease.115 Although this was not confirmed in a study of adults, increased frequency
of expression of CD45RO on circulating lymphocytes was demonstrated. This was
attributed to V8rJ8, cells, which, although decreased in number (possibly due to
sequestration in the gut), were more frequently of this 'memory' cell phenotype than
the equivalent population in healthy individuals.116 The preferential use of other Vy
and V8 T-cell receptor genes has been reported in coeliac disease,117118 but the
significance of this is not known.
Inflammatory bowel disease. In one published study of lymphocyte responses to
dietary antigens in Crohn's disease — a comparison of 11 Crohn's disease patients
with 9 normal controls — Sis to milk were statistically significantly increased (3.6
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c.f 1.4) in the disease group and there was a similar, but not significant, trend for
egg, wheat and soy.119
SUMMARY. Antibody responses to dietary antigens occur during the course of
normal development and are age-dependent. Quantitative and qualitative differences
occur in the presence of certain disease processes. In at least some of these, enhanced
antibody production might be attributable to altered permeability of the
gastrointestinal mucosa or impaired clearance of antigen. In others, there may be a
genetically determined predisposition to sensitisation to specific protein(s).
Cellular responses, as represented by proliferation of peripheral blood
lymphocytes, to dietary antigens also occur in normal individuals but there is
considerable variation between studies and between responses to different proteins.
There is, therefore, no consensus as to the expected magnitude of these responses in
the normal population. Atopic eczema with food sensitivity is perhaps the best
example of a pathology associated with a measurably increased response in peripheral
blood. However, the underlying mechanism of T-cell sensitisation to a specific dietary
antigen is best-established in the case of coeliac disease.
Yeasts as antigens
Of yeasts relevant to human health, the commensal and opportunist pathogen,
C. albicans, has been the most extensively studied with respect to the nature of the
immune response elicited by it. However, in studies of the structure of the molecular
species implicated as dominant antigens of C. albicans, S. cerevisiae has often been
used as a model. Experimental data on immune responses to yeasts can be more
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easily interpreted in the light of information on the chemical composition of cell wall
mannoprotein; therefore, this will be considered first. Much of the information in this
section is comprehensively reviewed in refs. 120-122.
Antigenic structure of mannan
Cell surface determinants which define serotypic differences between yeasts
are mainly, and perhaps exclusively, located on the structural mannans
(mannoproteins, peptidomannans), which constitute 20-23% of the cell wall, by
weight.123'124 In S. cerevisiae and C. albicans, the mural mannan consists of a
structural protein to which mannose polymers are covalently bound by two different
glycopeptide linkages:
i) TV, TV'-diacetylchitobiosylaspartamido (glycosylamine) bonds, by which linear
polysaccharides, with up to ~30 mannose residues in a 1—>6 linkage, are
attached to asparagine residues via TV-acetylglucosamine — these are said to
be W-linked' and recapitulate a joining sequence present in mammalian
glycoproteins;
ii) hydroxyamino acid ester bonds, by which short oligosaccharides, with up
to 4 mannose residues in predominantly al—>2 linkage, with some al—>3
terminal residues, are attached to serine or threonine — these are said to be
'O-linked' and have no mammalian counterpart.
In addition, the N-linked al—>6 polymannoside is further divided into an 'inner core'
and an 'outer chain'; these are both substituted with oligomannoside side-chains
similar to those 0-linked to the protein, but only those attached to the outer chain
have side-branches linked by phosphodiester bonds. Following ion exchange
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chromatography on diethylaminoethyl (DEAE) Sephadex, reactivity with antisera
against the parent yeast can be co-purified with mannan fractions with a high
phosphate content; therefore, variation in these O-phosphonomannans may be largely
responsible for serologically determined antigenic differences between species and
strains, i.e. they appear to contain major B-cell epitopes125 (there is firm evidence for
this in the case of C. albicans group B126). The obligate presence of a protein
component in mannan (which, depending on the method of purification, may be up
to 10% of the total weight127) testifies to the possibility that T-cell epitopes may be
present in the same molecule.
Mannans obtained from any given source are heterogeneous both with respect
to molecular weight128 and charge.129 In addition, they can be altered by the method
of purification: for example, the alkaline conditions associated with precipitation with
Fehling's solution result in a lower molecular weight product (-40 kD)130 due to loss
of O-linked oligomannosides and cleavage of some peptide bonds — this product,
when obtained from C. albicans, will bind antibody raised against crude extracts of
yeast cell wall but not stimulate its production {i.e. it is antigenic but not
immunogenic);123,131 nor is it an efficient stimulator of proliferation in lymphocyte
cultures (an observation partly, but not completely explained by interference from
residual bound copper).132,133 In contrast, mannan precipitated with
cetyltrimethylammonium bromide (cetavlon, CTAB) retains a high molecular weight




It is a long-standing observation that crude extracts of soluble material derived
from C. albicans have the ability to stimulate in vitro lymphocyte proliferation.134-136
Because of the known importance of mannan as the dominant antigen in humoral
immune responses to yeasts, speculation arose as to whether it might also be the agent
responsible for these cellular responses. On investigation, it became clear that, even
though different mannan-containing preparations might react equally with pre-formed
antibody, they varied greatly in their ability to induce an antibody response and to
effect lymphocyte proliferation. For example, Gettner and MacKenzie137 found
mannan precipitated with Fehling's solution to be a very poor stimulator of
lymphocyte proliferation unless it was adsorbed on to latex particles. Durandy et al.138
absorbed the same mannan preparation with methylated bovine serum albumin, and
showed that this rendered it able to induce a lymphoproliferative response and to
stimulate in vitro T-cell-dependent production of antibody which was reactive with
the unabsorbed mannan. Wirtz et al.139 found that a 'partially purified polysaccharide
fraction' (MPPS), extracted under mild conditions, induced lymphocyte proliferation,
whereas a more degraded mannan preparation did not, even though they competed for
binding of rabbit anti-Candida antibody.
Piccolella et al.140 co-cultured T-cells (as sheep erythrocyte-rosetting, E+, cells)
and B cells (as non-rosetting, E~, cells, further depleted of monocytes by adherence)
in the presence of MPPS, and showed that the resulting proliferative response was
sensitive to mitomycin C treatment of the T-cell component, whereas similar
treatment of the B-cell population left the response relatively intact. They went on to
demonstrate a requirement for cells expressing la antigen {i.e. MHC class II),141 and
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that this function could be subserved by monocytes/macrophages142 (although they
had previously considered only B-cells to be capable of this).
Ausiello et al.143 also demonstrated differential lymphocyte responses to
various mannan preparations. One of these — a neutral citrate buffer extract, termed
GMP (probably identical to MPPS), containing mannose as 98.4% of the total
polysaccharide, with 8% protein — was particularly active. It was found to stimulate
uptake of tritiated thymidine in peripheral blood mononuclear cells but not umbilical
cord blood mononuclear cells. Together with the inhibition ofproliferation by an anti-
DR monoclonal antibody, this was taken to imply antigen-specificity of the T-cell
response. GMP was also shown to induce non-MHC-restricted cellular cytotoxicity
in mice144 and man.145
Torosantucci et al,146 subjected GMP to pronase digestion, which abolished its
lymphocyte-stimulating ability but preserved its antibody-binding capacity. The
lymphoproliferative response was also abolished by a non-mitogenic anti-CD3
monoclonal antibody. On fractionation by ion-exchange chromatography, the
lymphocyte-stimulating capacity of GMP co-separated with a fraction containing a
high molecular weight band (>200 kD) on SDS-PAGE. The composition of this
fraction, which constituted 47.6% of the original material, was >90% mannose and
5% protein.
Podzorski et al.133 performed lymphocyte proliferation assays with mannans
prepared by precipitation with Fehling's solution or CTAB, and demonstrated that
CTAB precipitation preserved immunological activity which was partially lost as a
consequence of Fehling's precipitation, confirming the importance of the native
structure of mannan to its effectiveness as a T-cell antigen.
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Durandy et alH1 found evidence for predominant DQ restriction of the T-cell
response to mannan. However, the preparation used in this study was the methyl-
BSA/Fehling's precipitated mannan previously used by this group (see above), and
confidence in this finding would be enhanced if it could be reproduced with an
unmodified mannan preparation.
SUMMARY. Yeast cell wall mannans are the immunodominant antigens in humoral
immune responses to these organisms. Mannans are similar in overall chemical
composition, but differences in fine structure determine the species- and strain-
specificity of the antibody response. Antibody responses to mannans are T-cell-
dependent. T-cell responses to mannans are classical antigen-specific responses which
require antigen-presenting cells, are MHC-restricted, and depend on the relative
intactness of the protein component of the mannan.
Notes on techniques
Measurement of antibodies
As discussed above, studies of antibodies to dietary antigens have often
yielded conflicting results. No doubt, this is partly due to sampling error, but the wide
variety of techniques used is likely to have been a major contributor. The earliest
antibody assays had end-points which relied on some measure of secondary
manifestations of antibody-binding, such as haemagglutination, precipitation or
complement activation. These depend on functional characteristics of immunoglobulin
molecules which differ between isotypes. Primary binding assays measure bound
antibody regardless of biological function and they are also more sensitive. For
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example, McCaffery et al.148 compared the Farr assay with haemagglutination and gel
precipitation for the measurement of anti-BSA in patients with inflammatory bowel
disease and healthy controls — the Farr assay detected anti-BSA in 23% of controls,
42% of Crohn's disease subjects and 37% of those with ulcerative colitis, gel
precipitation (micro-Ouchterlony double diffusion) was negative in all cases, and
haemagglutination was positive in less than half of the samples with a high binding
capacity in the Farr assay. Furthermore, it is clear that in comparisons between
groups, different results might be arrived at depending on whether the data being
compared are based onprevalence (all-or-nothing, descriptive, response) or magnitude
(numerical response).
The use of ELISA for antibody measurement was first described by Engvall
and Perlmann,149 and rapidly gained widespread acceptance in a variety of
applications for assessing serological responses in infectious diseases.150 Apart from
the introduction of disposable microplates to replace tubes as solid phase supports,151
the basic technique remains largely unchanged since its original description. A major
advantage of ELISA is that it allows accurate standardisation.
Previous attempts to measure serum antibodies to Saccharomyces cerevisiae
have taken absorbance alone as the end-point of the assay, or have relied on the
concept of a 'binding index'. Although both of these approaches represent valid
attempts to produce quantitative data, there are significant objections to them. Firstly,
neither allows discrimination between samples giving absorbance values at or near the
upper end of the range which is measurable (or, in practice, encountered under the
conditions of the assay). Secondly, even if inter-assay standardisation is attempted by
kinetic monitoring of the colour development reaction and taking all the readings
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when a particular reference well (or wells) has achieved a predetermined absorbance
value, it cannot be assumed that the shape of the (implied) titration curve described
by the reaction will be constant each time the assay is performed; in effect, this is a
single-point calibration.
In order to obviate these problems in the experimental work described here,
ELISAs were developed in which the antigen-binding activity of test sera could be
derived from calibration curves generated by serial dilutions of constant standard sera.
Since a new curve is created each time the assay is performed, it is internally
controlled for variations in conditions, such as temperature and incubation times.
Furthermore, test samples giving absorbance values occupying the upper plateau of
the calibration curve can be correctly quantified after further dilution. The practical
considerations inherent in this approach have been discussed.152
Lymphocyte culture
The ability to establish cultures of lymphocytes in vitro has been fundamental
to the development of current knowledge ofbasic immunological processes. However,
many potential sources of error exist when these techniques are used to derive
quantitative data, and it is worth considering these in the context of the historical
development of the various methods which have been used in this thesis. (A very
informative review of the early history of lymphocyte culture is contained in
reference 153.)
Proliferation assays. In effect, it was the discovery (more correctly, rediscovery) of
the haemagglutinating effect of an extract of the red kidney bean Phaseolus
vulgaris154 which was the starting point for the development of cellular immunology.
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Use of this phytohaemagglutinin (PHA) to facilitate the preparation of leucocyte-rich
cell fractions from blood or marrow led to the fortuitous observation that it appeared
to stimulate mitosis in a proportion of the leucocytes thus obtained.155 Before this, it
had been uncertain how much, if any, capacity for division was retained by cells in
the peripheral blood, and the first practical use made of this phenomenon was in the
production of cellular preparations for chromosome analysis.156'157 However, since the
proliferating cells appeared to be the small lymphocytes,158 whose central role in the
generation of immune responses was now being realised, it was clear that the ability
of any agent to stimulate these cells in vitro was of great physiological interest per
se. It was soon evident that other substances also demonstrated the property of
'mitogenicity' in lymphocyte cultures — first shown for purified protein derivative
(PPD) of Mycobacterium tuberculosis,159 this observation was rapidly extended to
many further examples, including other microorganisms and their products (diphtheria
toxoid, pertussis, smallpox and polio vaccines, streptolysin O, filtrates of E. coli),
allergens (grass pollen, ragweed, alternaria) and drugs (penicillin, aspirin, phenytoin
and others).160"169 Significantly, there were three important differences between the
response to PHA and those to the great majority of other substances tested: it
occurred earlier, involved a much greater proportion of the cells present at the start
of the culture, and it did not depend on prior sensitisation of the subject.160'161,170,171
It was, therefore, suggested that the mechanism of action of PHA might differ from
that of 'specific' antigens; the fact that its mitogenic activity could be abolished by
absorbing out its leucoagglutinating activity161 lent weight to the suggestion that it
might act by binding to surface moieties on the lymphocyte in a way analogous to
its cross-linking of red cell surface polysaccharides.172 Apart from its value to the
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study of fundamental immunological processes, the polyclonal T-cell response to PHA
was also found to be of some use in the investigation of primary and secondary
cellular immunodeficiencies,173"177 and, although a very non-specific test, it continues
to be applied in this clinical context.
A major difficulty encountered in early studies was the problem of
quantitation of proliferative responses, which initially had to be assessed subjectively
on the basis of direct visualisation of morphological changes (such as '% blastic
transformation' and numbers ofmitotic figures). Even after allowing for sampling and
counting errors, the inferences to be taken from microscopic observation were not
always obvious — for example, the apparent percentage blast transformation in a
culture will depend not only on the proportion of the original cells transformed but
also on the amount of cell proliferation and death.178 Although some attempts were
made at standardisation of morphological data,179 considerable simplification resulted
from the use of radio-labelled DNA precursors, whose incorporation into cellular
DNA, during a timed incubation, could be readily estimated, either directly, on
washed, dried cells, or following chemical extraction with trichloroacetic acid. Of the
several agents employed — [14C]-thymidine,180 [3H]-thymidine,178 [l25I]-iodo-
deoxyuridine181 and [32P]-sodium orthophosphate182 — tritiated thymidine became
established and is in current use.
The impetus for the development of further methodological improvements,
which aimed to optimise the sensitivity, reproducibility and ease of execution of the
technique, followed the discovery of in vitro alloreactivity — the observation that
lymphocytes from different individuals were co-stimulated in mixed cultures,183 and
that these data correlated both with the clinical survival of tissue grafts184 and with
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the degree of histocompatibility assessed serologically.185 The major advance of
relevance to modern practice was the replacement of 'bulk' cultures, carried out in
tubes,186-188 by miniaturised, semi-automated techniques which allowed multiple assays
to be performed in disposable plastic multi-well plates, the final product being
harvested directly on to glass fibre filters before p-counting in liquid scintillant.189 197
Although some groups have favoured the use of very small volume cultures (~20 pi)
in the wells of Terasaki plates,198-209 and have produced impressive results with that
system, it has not been universally adopted, probably because it is more technically
demanding. Currently, quantitative lymphocyte proliferation assays are almost
universally carried out in 96-well polystyrene plates, which is the technique used in
the work reported here. In addition, isolation of mononuclear cells, with minimal
erythrocyte or granulocyte contamination, was made easier and more reliable with the
introduction of density gradient centrifugation techniques.210
It is well documented that these assays are very sensitive to variations in
virtually any of the conditions under which they are carried out; it is important that
this is borne in mind when attempting to derive quantitative information from them,
and that every effort is made to standardise as much of the procedure as possible.
Precursorfrequency analysis. Although the techniques described above have proved
valuable in permitting qualitative and semi-quantitative measures of certain aspects
of immune function, there is such variability in the exact magnitude and timing of
responses within and between experiments that it is not possible, under any given
conditions, to assess what proportion of the cell population (the precursor frequency)
present at the initiation of the culture is responding to the applied stimulus. In order
to address questions of this nature, the method of limiting dilution analysis (LDA) has
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been applied.172'211-213 The theoretical basis of LDA is that inferences can be made
from statistical analysis of culture systems in which one or more of the participating
cell types are present in limiting amounts — i.e. they are so infrequent that a
measurable proportion of 'replicate' cultures will receive no cells of that type. In its
simplest form, only one cell type is limiting and all other components of the culture
are non-limiting, i.e. available in sufficient excess as to render the experimental
conditions fully permissive to the limiting cell type, allowing the original presence
of as few as one of these in the initial culture to be detected by some suitably
sensitive end-point assay (e.g. [3H]-thymidine uptake, cytotoxicity, antibody or
cytokine secretion).
If a number of 'replicate' cultures are established in which the limiting cell
type is present at a mean frequency of p. cells/well, then the probability, Px, of any
well containing x cells is defined by the Poisson probability distribution214 as:
P = e
x\
This probability equates to the expected value of the fraction, Fx, of the total number
of wells in the experiment which originally contained x of the limiting cell type.
Because the end-point measurement is an all-or-nothing response (i.e. wells are either
'positive' or 'negative', but the initial number of responders in any positive well is
not known), only the fraction of wells for which x = 0 — the 'negative' wells — can
be directly determined experimentally. From the zero term of the Poisson distribution:
F = e1
o *
Now, p = <f)c, where § = the proportion of cells of the limiting type in the sample
being tested, and c = the mean number of sample cells per well (often called the cell
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input), therefore:
F = e ~*cro e
=> -lnF0 = <j)c
Thus, a plot of —In F0 (in practice, F0 on a log scale) against c will yield a straight
line through the origin; the unknown precursor frequency, <j), can be calculated from
the gradient, or from the value of 1/c when F0 = 0.37 (i.e. p = 1 — there is an
average of one limiting cell per well at that value of c).
This is the situation when the system conforms to a single-hit model, where
only one limiting cell in a well is necessary and sufficient to give a positive result.
It is necessary to derive F0 at different values of c in order to assess the 'goodness-of-
fit' of the experimental data to the single-hit model — any significant departure from
linearity suggests the possibility of a more complex system, e.g. multi-hit (two or
more of the same cell type necessary for a response), or multi-target (two or more
different cells necessary). The relative suitability of different statistical methods of
data-fitting for the calculation of precursor frequency (minimum chi-square,215
maximum likelihood,216 jacknifed maximum likelihood217) and for analysing goodness-
of-fit (chi-square,215 log likelihood and modified Weibull218) has generated some
debate, but it has been asserted that uniformity of approach is the most important
factor for obtaining meaningful comparisons.212
Examples ofLDA, using an end-point of T-cell [3H]-thymidine uptake, include
measurements of the frequency of circulating specific precursors responding to PPD,
tetanus toxoid, M. leprae and Leishmanial9 221 and of precursors in umbilical cord
blood recognising mycobacterial 65 kD heat-shock protein.222 LDA is currently being
explored as a method of assessing the potential for clinically significant alloreactivity
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in the context of bone marrow transplantation.223,224
Long-term culture and T-cell cloning. Although it had been possible to chronically
establish certain B lymphoblastoid cells as a consequence of their transformation with
Epstein-Barr virus, the earliest long-term cultures of T-lymphocytes were restricted
to examples of neoplastic cell lines and alloreactive cells maintained by repeated
stimulation with the relevant allogeneic cells. Despite the ease with which fresh
PBMC demonstrated an initial proliferation in response to mitogens and soluble
antigens, simple attempts to restimulate with these agents were ineffective.
The solution to this impasse was provided by the observation that growth of
normal T-cells from marrow or blood could be initiated and prolonged by
supplementation with conditioned medium from other cultures of PHA-stimulated
cells.225'226 Kurnick et al111 using conditioned medium in this way, were able to
maintain long-term growth of cells following initial stimulation with mitogen (PHA)
or antigen (PPD or allogeneic cells). Significantly, the growth-maintaining properties
of the conditioned medium were not diminished (in fact, were enhanced) by removal
of the PHA content, a manipulation which did, however, render the medium incapable
of initiating growth in unstimulated cells. Thus, the presence of an active principle
quite separate from the contaminating lectin was established — originally designated
T-cell growth factor (TCGF), it is now recognised as IL-2. When the initially antigen-
stimulated cells were grown in conditioned medium and later tested in proliferation
assays, they were shown to have retained their specificity. Furthermore, whereas
allogeneic cells were a sufficient stimulus for the alloreactive cell line, the cells with
specificity for soluble antigen (PPD) required the addition of fresh syngeneic cells in
order to proliferate (in contrast, the response to PHA of cells from long-term culture
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could be restored with syngeneic or allogeneic cells). Subsequent studies confirmed
the importance of MHC class II molecules as restriction elements for responses to
soluble antigen.228
The ability to selectively enrich cell populations for a particular antigen
specificity allowed the use of limiting dilution cultures for the cloning of T-cells of
predetermined specificities.229-232 Clones have proven especially useful in the
investigation of MHC restriction of T cell responses because alloreactive cells have
been selected out of the population,233'234 thereby unmasking the unreactivity of certain
histoincompatible MHC/ antigen combinations and allowing detailed scrutiny ofMHC
cross-reactivity. Conversely, allospecific clones can be selected for and investigated
in similar manner.235'236 T-cell clones specific for a wide variety of antigenic
substances with relevance to clinical practice237-239 are a useful tool for investigating







Development of quantitative ELISAs
Preparation of coating antigens
Sacc. An aqueous extract of a commercial preparation of Saccharomyces cerevisiae
was prepared as follows:
200 g dried bakers' yeast (J. Sainsbury, pic) were rehydrated by suspending
in 1 1 pre-cooled (4 °C) distilled water, with constant mixing. The suspension was
centrifuged at 2,000 rpm (~800 x g) in a Beckman TJ-6 centrifuge, the supernatant
discarded, and the yeast resuspended to the original volume, the process being
repeated for a total of three washes. The final suspension was heated to 100 °C for
1 hour in a boiling water bath and then cooled to 4 °C. After centrifugation, the
supernatant was retained, filtered to 0.45 pm, dialysed extensively against distilled
water and lyophilised. The resulting pale yellow-brown powder (sacc) was stored at
room temperature.
Casein. Dried bovine milk casein was obtained from a commercial source (Sigma).
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Determination of optimal antigen concentration
In order to determine appropriate concentrations for the antigen solutions used
to coat ELISA plates, experiments were conducted using a 'checquerboard' design.
Sacc. Solutions of sacc, in doubling dilutions from 4 pg/ml to 1.95 pg/ml, were
prepared in carbonate-bicarbonate buffer, pH 9.6 (see Appendix I). Aliquots of 100 pi
of each of these solutions were deposited into the wells of Immulon 2 ELISA plates
(Dynatech), using two rows of wells for each dilution. The plates were then sealed
with adhesive tape, agitated briefly on a plate shaker, and incubated for 24 hours at
room temperature. Immediately before use, the plates were washed four times with
phosphate-buffered saline containing 0.05% Tween 20 (Sigma) (PBS-Tween, see
Appendix I). Doubling dilutions, from 1/25 to 1/214 in PBS-Tween, of normal
('negative') and hyperimmune polyclonal ('positive') rabbit serum" were then
overlaid onto the coated plates — 100 pi of each dilution of the positive and negative
sera into one well for each concentration of coating antigen — the plates resealed,
agitated, and incubated for 1 hour at 37 °C. Following a further four washes with
PBS-Tween, 100 pi of a 1/1,000 dilution of horse-raddish peroxidase-conjugated swine
anti-[rabbit immunoglobulin] (Dako) in PBS-Tween were added to each well, and the
plates resealed, agitated, and incubated for a further hour at 37 °C. After four more
washes, 100 pi ofo-phenylenediamine (OPD) (Sigma), 0.4 mg/ml in phosphate-citrate
buffer, pH 5 (see Appendix I), activated with 1:5,000 v/v of 30% hydrogen peroxide
(Sigma), were added to each well, and the plates left at room temperature during the
development of the colour reaction. The latter was stopped after 5 minutes by the
addition of 100 pi of 1 M sulphuric acid to each well, and the optical density
a: these sera were prepared in-house by Mrs. S. Allen
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(absorbance) at 492 nm (A492) read on an ELISA plate-reading spectrophotometer
(Titertek Multiscan II).
Casein. A similar procedure was followed in the case of casein: dilutions of the
antigen were tested at approximately semilog intervals from 100 pg/ml to 0.03 pg/ml,
with hyperimmune and normal rabbit sera in doubling dilutions from 1/50 to 1/25,600.
Derivation of standards
In order to produce standard antisera for calibration of the assays, individual
sera were screened at a single dilution for the presence of IgG and IgA anti-sacc
antibodies and IgG anti-casein antibodies. The sera used were from patients with
gastroenterological disorders; 69 were screened for IgG anti-sacc, 70 for IgA anti-
sacc, and 51 for IgG anti-casein.
Sacc. ELISA plates were coated with sacc antigen at optimal concentration, as
described above. Sera were diluted 1/200 in PBS-Tween and the assay was conducted
essentially as above, except that the peroxidase-conjugated antisera used were rabbit
anti-[human y-chain] and rabbit anti-[human a-chain] (Dako) at 1/1,000 dilution, for
the detection of IgG and IgA isotype-specific antibodies, respectively.
Casein. ELISA plates were coated with casein at optimal concentration and sera were
screened at i/lOO dilution.
Sera which gave high absorbance values were then pooled to provide a
separate calibration standard for each assay.
Assay calibration and calculation of test results
Aliquots of the IgG and IgA anti-sacc, and the IgG anti-casein, calibrants were
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stored at —30 °C.
Each time the ELISA was performed, an aliquot of each of the appropriate
calibrants was thawed and serial doubling dilutions made. Test sera were diluted to
l/l00. The dilutions of the calibrants and test sera were then assayed using 100 pi/we 11
in duplicate wells. The IgG- and IgA-specific peroxidase conjugates used were as
described above, and, in the final form of the assays, 71/2 minutes were allowed for
colour development in the sacc assays, and 5 minutes in the casein assay, before
quenching the reaction.
Calibration curves were compiled from the absorbance values obtained at each
dilution of the calibrants — mean values from duplicate wells were plotted against
reciprocal dilution (on a log scale) and a sigmoid curve fitted by computer, using a
graphics program (FigP).
A subjective judgement was made as to the 'useable' part of the curve —
where the gradient was sufficient to adequately resolve differences in concentration
— and the test sample absorbance values lying within this range were transformed
to equivalent dilutions of the calibrant. By correcting for the sample dilution factor,
antibody concentration of the undiluted sample could then be expressed as a
proportion (%) of that of the undiluted calibrant. Duplicate results were obtained for
each sample, and the means taken. Test samples giving absorbance values above the
upper acceptable limit at t/100 dilution were re-tested at further doubling dilutions
until a concentration value could be assigned to them.
Assay variability
The variability of the assays was assessed in the course of their use in testing
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the normal and pathological sera whose results are discussed below.
Intra-assay variability. This was assessed on the results obtained from a large
number of consecutively tested samples. The difference between each pair of
duplicate result was expressed as a proportion of their mean. The set of values thus
obtained could then be described statistically.
Inter-assay variability. This was assessed by testing a small number of selected sera
on several occasions. Statistical analysis was performed on the means of the duplicate
values obtained from each assay. (It can be seen that a component of this variability
will, in fact, be determined by intra-assay variability — the true inter-assay variability
would be assessed by analysing the distribution of the mean values derived from a
large number of replicates; however, the method used here reflects the inter-assay
variability observed in practice, given that samples were always assessed in
duplicate.)
Application to human sera
Subjects
Venous blood samples were collected from 224 normal subjects who acted as
controls; 179 of these were blood donors attending the Liverpool blood transfusion
centre and the remainder were laboratory staff. Samples were also obtained from 163
patients with selected gastrointestinal disorders, most of whom were under the care
of a single consultant physician. The study received ethical committee approval and
the patients' permission was obtained for their inclusion.
Sera were separated and stored at —20 to —30 °C until required.
The allocation of patients to each disease category was based on the clinical
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diagnosis at the time of sampling, in conjunction with a review of the case notes.
Demographic data pertaining to the different groups are summarised in Table 1.
Sex ratio
Group Total no. (m:F) AGE (median; range)
normal 224 2.3 36; 21-58 206
Crohn's disease 51 0.85 50 40; 20-76 46
non-specific colitis 24 0.85 61; 22-73
ulcerative colitis 41 0.71 43; 24-82 40
chronic liver disease 23 0.44 58; 38-77 21
coeliac disease 17 0.13 55; 36-72 16
irritable bowel 7 0.4 40; 23-56
Table 1. Age and sex data ofpatients and controls. Small italics denote the number of observations
in cases where data was incomplete.
Site, activity and duration of Crohn's disease. Of the Crohn's group, 32 were
identified as having small bowel disease, with or without large bowel involvement,
14 were considered to have large bowel disease only, and 1 patient had oesophageal
Crohn's disease.
Disease activity was assessed by means of the Bristol Activity Index, as
described by Harvey and Bradshaw,240 and by measurement of serum a,-acid
glycoprotein (AAG, orosomucoid) by rate nephelometry (Beckman Array). The upper
limit of the normal reference range for AAG was 1.2 g/1.
An estimate was made of the likely duration of disease, based, as far as
possible, on the duration of symptoms.
Treatment of inflammatory bowel disease. Potentially immunomodulatory therapy
taken by patients at the time of entry into the study was documented (Table 2).
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Aetiology of liver disease. There were 10 patients with alcoholic liver disease (7 of
whom had frank cirrhosis), 4 with chronic active hepatitis, 5 with primary and 1 with
secondary biliary cirrhosis, 2 with cirrhosis of unknown aetiology and 1 with
undefined chronic liver disease.
Coeliac disease. These patients were all being maintained on a gluten-free diet.
Group
Corticosteroids 5-ASA derivative
(oral; topical; both) Azathioprine (oral; topical)
Crohn's disease (49) 22
Non-specific colitis (24) 5




Table 2. Drug treatment in patients with inflammatory bowel disease. Small italics denote the number
of subjects for whom this information was available.
Statistical analysis
Antibody levels were compared between groups by the Mann-Whitney (7-test,
and numbers of positive results by Fisher's exact test. AAG levels were compared by
the two-sample Mest (unless otherwise stated in the text). The sign-interval test was
used to calculate 95% confidence intervals (CIs) about medians and the f-interval test
for CIs about means. Correlation was assessed using Pearson's product moment






For each concentration of coating antigen, corresponding pairs of titration
curves were compiled from the results obtained with positive and negative sera (Fig.
1 & 2).
At low antigen concentrations, non-specific binding of immunoglobulin in the
negative sera was relatively high, presumably due to the availability of binding sites
on the plate which were not taken by antigen, and decreased with increasing antigen
concentration. However, specific binding of immunoglobulin from the positive sera
was seen to diminish quite markedly at high antigen concentrations (especially for
sacc) — this latter effect is well-recognised and may be due to steric hindrance from
excess antigen bound to the surface of the plate or adsorption of specific
immunoglobulin by excess antigen which is loosely bound and therefore more readily
eluted during the washing steps.
For the purposes of further experiments, an optimal coating concentration of
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Assay standards
The absorbance values obtained by screening sera at a single dilution are
shown (Fig. 3). Equal volumes of the sera represented by open circles (8 for IgG
anti-sacc, 4 for IgA anti-sacc, and 7 for IgG anti-casein) were later pooled to produce
calibration standards for each of the specific antibody assays
Representative examples of the calibration curves obtained using the IgG and
IgA anti-sacc, and the IgG anti-casein, standards are shown (Fig. 4 & 5).
Assay variability
Intra-assay variation was very low (<3%) for all three assays (Table 3).
Inter-assay variation was less than 10% for the IgA anti-sacc assay and for the
IgG anti-casein assay, but up to 20% for the IgG anti-sacc assay (Table 4). This latter
may be an overestimate because the aliquots of serum used had been prediluted prior
to freezing — subsequent experience suggests that this may be a factor contributing


































Figure 3. Scatterplot showing absorbance values obtained by screeningserafor antibodies to a) sacc,
and b) casein. All data have been grouped at intervals of 0.1 absorbance units. Open circles denote
sera which were later pooled for use as calibrants.
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reciprocal dilution
FIGURE 4. Standard curves obtained with the IgG and IgA anti-sacc calibrants. Dashed lines enclose
the part of the curve used to calculate test results.
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reciprocal dilution
FIGURE 5. Standard curve obtained with IgG anti-casein calibrant. Dashed lines enclose the part of
the curve used to calculate test results.
Relative difference between duplicates (%)
Assay n (median; 95% C.I.)
IgG anti-sacc 411 2.9; 2.7-3.3
IgA anti-sacc 132 2.1; 1.5-2.9
IgG anti-casein 267 2.8; 2.4-3.6
Table 3. Intra-assay variation ofELISAs. The number ofsamples included in each analysis is denoted
by n.
Antibody binding
Assay Sample ID n (mean; range) CV (%)
IgG anti-sacc 213 10 1.3; 1.0-1.6 19
220 18 5.9; 4.6-7.7 15
IgA anti-sacc 220 15 1.8; 1.6-2.1 7.3
IgG anti-casein 105 11 2.5; 2.2-2.8 9.7
132 12 20.6; 18.7-22.3 6.0
145 12 32.2; 29.1-35.1 4.7
82 12 60.4; 51.9-72.2 9.0
Table 4. Inter-assay variation ofELISAs. The number of times each sample was analysed is denoted
by n.
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Anti-sacc antibodies in health and disease
IgG ANTI-SACC
The results of measurement of IgG anti-sacc in the different groups of subjects
are shown in Table 5. For the purposes of analysis, sera with IgG anti-sacc below the
lowest value which could be quantified were assigned a value of half the limiting
value for that particular assay.
Sample distributions were non-normal and were compared using the non-
parametric Mann-Whitney test. Both the Crohn's and chronic liver disease groups had
IgG anti-sacc levels which were higher than in the normal controls, the differences
remaining significant even when corrected for the number of comparisons made.
Group n Median; 95% c.i. No. of low values P
normal 224 2.0; 1.8-2.4 11 (4.9%) —
Crohn's disease 51 6.6; 3.9-12.2 1 (2.0%) <0.0001
non-specific colitis 24 1.4; 1.2-2.3 2 (8.3%) NS
ulcerative colitis 41 2.3; 1.4-3.1 7 (17.1%) NS
chronic liver disease 23 3.7; 2.1-5.8 0 <0.005
coeliac disease 17 3.0; 2.6-4.0 0 NS
irritable bowel syndrome 7 1.4; 0.7-4.8 1 (14.3%) NS
table 5. IgG anti-sacc antibodies. P values are uncorrectedfor the number of comparisons. 'Low
values' denotes sera which were arbitrarily assigned the value of half the lower limit for the assay.
IgA ANTI-SACC
In the case of IgA anti-sacc, because the proportion of sera with
unquantifiably low values was large, use of the Mann-Whitney test was considered
inappropriate. Fisher's exact test for 2 x 2 contingency tables was therefore used to
compare groups on the basis of the number of sera with IgA anti-sacc above the
estimated 95th. centile for the normal controls, values above this level being
considered 'positive'. Again, a significant result was obtained for both the Crohn's
and the chronic liver disease group, although, in the latter case, the P value was not
significant after correction (Table 6).
Group n no. of low values no. "positive" P
normal 224 180 (80%) 12 (5.4%) —
Crohn's disease 51 23 (45%) 17 (33%) 3 x IO¬
non-specific colitis 24 20 (83%) 0 NS
ulcerative colitis 41 25 (61%) 5 (12%) NS
chronic liver disease 23 12 (52%) 5 (22%) 0.013
coeliac disease 17 12 (71%) 1 (5.9%) NS
irritable bowel syndrome 7 6 (86%) 0 NS
Table 6. IgA anti-sacc antibodies. P values are uncorrected. Positive values were defined as being
greater than the estimated 95th. centilefor the normal controls (1.81% of the calibrant). Low values
are those which could not be quantified {N.B. not synonymous with negative values}.
Fig. 6 illustrates graphically the anti-sacc antibody results for the Crohn's and
normal groups. Fig. 6b shows how the shape of the distribution of IgA results was
affected by the number of unquantifiable values for this isotype (represented by the














































FIGURE 6. Frequency histograms showing the distributions of a) IgG, and b) IgA isotype-specific
antibodies to sacc in normal subjects and Crohn's disease patients. For clarity, the raw data were log-
transformed, grouped at intervals of 0.1 and plotted on a linear scale; data from the disease group
have been plotted as negative values.
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Further observations in normal subjects
Sex. There was considerable over-representation ofmales among the normal subjects.
However, there was no difference between sexes for IgG anti-sacc (males: 1.96,
1.75-2.43; females: 2.16, 1.70-2.65; P > 0.94). In the case of IgA anti-sacc, a higher
proportion of positive sera in males also failed to reach statistical significance (males:
11/156 positive; females: 1/68 positive; P = 0.11).
Age. There was no correlation between the age of the subjects and the IgG anti-sacc
value (r = 0.067, P - 0.34). Neither was there a correlation between age and IgA
anti-sacc after estimating low values in the same way as for IgG (r = —0.026, P =
0.71); as an additional check, the number of positive results were compared between
subjects below the median age of 36 years and those above the median age (4/94 and
6/102, respectively; P = 0.75).
Further observations in Crohn's disease patients
Site ofdisease. A comparison was made within the Crohn's disease group according
to whether small bowel disease was present or not. IgG anti-sacc was higher in the
presence of small bowel disease, but this observation just failed to reach statistical
significance (small ± large bowel disease: 11.4, 4.0-16.2; large bowel disease: 3.8,
2.1-5.5; P = 0.058). There was no difference in the proportion positive for IgA anti-
sacc (small ± large bowel disease: 12/32 positive; large bowel disease: 3/14 positive;
P = 0.33). Patients with or without small bowel disease did not differ with respect
to severity (AAG 0.95, 0.76-1.15 and 0.95, 0.82-1.37 g/1, respectively; P = 0.53,
Mann-Whitney. AAG above the upper limit of the normal reference range in 9/32
patients with small bowel disease and in 5/14 of those without small bowel disease;
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P = 0.73) or duration of disease (78, 46-216 and 61, 21-216 months, respectively;
P = 0.40, t-test).
Duration ofdisease. Information was available for 46 patients. The median (95% CI)
duration was 7 (4.5-13) years. There was no correlation between duration of disease
and IgG anti-sacc (r = 0.24, P = 0.11), but a positive correlation was found between
duration and IgA anti-sacc (r = 0.38, P = 0.01). However there was no difference in
the number of positive IgA values between the lower and upper half of the
distribution of disease duration (4/23 and 10/23 positive, respectively; P = 0.11).
The age was known in 47 patients. There was a highly significant correlation
between age and duration of disease (r = 0.50, P = 0.0006). However, as with normal
subjects, there was no correlation between age and IgG (r = 0.017, P = 0.91) or IgA
anti-sacc (r = —0.015, P = 0.92; 8/23 positive values below the median age and 7/23
above; P = 1). Therefore, differences due to age are unlikely confounders in the
above analysis. There was no correlation between duration or age and severity of
disease (r = —0.111, P = 0.46 and r = —0.127, P = 0.40, respectively).
Treatment. Median IgG anti-sacc in those patients taking steroid medication was no
different from that in those who were not on this treatment (6.1, 3.5-16.0 and 6.6,
1.8-12.1, respectively; P = 0.37). IgA anti-sacc was positive in 7/23 of those on
steroids and 7/25 of the others (P = 1).
Severity of disease. Serum AAG was obtained for all normal and Crohn's disease
subjects; a Bristol Activity Index score was available for 38 of the Crohn's disease
group. Serum AAG was above the upper limit of the normal range in 16 Crohn's
disease patients. It was also higher in this group as a whole, compared with the
control subjects (1.10, 0.97-1.23 and 0.74, 0.72-0.76 g/1, respectively; P < 0.0001)
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and correlated with the Bristol Activity Index score (r = 0.76, P = < 0.0001).
Although there was no overall correlation between AAG and IgG anti-sacc (r =
0.056, P = 0.70), IgG anti-sacc was significantly higher in Crohn's disease patients
with an AAG above the normal range, compared with those with normal AAG (13.8,
4.92-19.1 and 5.01, 2.44-10.7, respectively; P = 0.03). There was no correlation
between AAG and IgA anti-sacc (r = — 0.21, P = 0.13; 5/25 positive in lower half
of AAG distribution and 12/25 in upper half; P = 0.072); a higher proportion of IgA-
positive samples among patients with a high AAG was not statistically significant
(8/16 and 9/35, respectively, P = 0.12).
IgG ANTI-CASEIN
As a test of whether the above result for the Crohn's disease and chronic liver
disease groups could be generalised to another dietary antigen, these sera, and those
of the controls, were tested for IgG anti-casein. No significant differences were found
between the controls and either disease group (Table 7 and Fig. 7).
Group n Median; 95% c.i. no. of low values
normal 222 7.9; 6.2-10.8 23 (10.4%)
Crohn's disease 51 7.4; 5.2-13.0 3 (5.9%)
chronic liver disease 23 6.9; 4.4-10.5 3 (13.0%)























Figure 7. Frequency histogram showing the distribution of IgG anti-casein antibodies in normal







Peripheral blood mononuclear cells (PBMC)
PBMC were separated over ficoll by the method of Boyum.210 Over time,
minor empirical adjustments to the technique were made, and the final form is
described here.
Aliquots of whole blood were collected from donors by venepuncture and
diluted with an equal volume of sterile PBS containing preservative-free heparin to
give a final concentration of 15 u/ml. This mixture was carefully decanted onto a
Lymphoprep (Nycomed) density gradient and centrifuged at 600 x g (1,637 rpm") for
20 min. at 20 °C. The mononuclear cell layer at the plasma/ficoll interface was
removed by pipette and the cells washed once in an excess of sterile PBS, followed
by centrifugation at 400 x g (1,337 rpm) for 15 min at 20 °C. The supernatant was
discarded and the cells were resuspended in a small volume of complete culture
medium. After adding a small aliquot of the suspension to an equal volume of trypan
a: speeds are quoted for the Mistral 3000i centrifuge
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blue dye, a manual count of viable cells was obtained using a haemocytometer
counting chamber (modified Neuebauer), and corrected for the dilution factor. Cells
obtained by this method were virtually 100% viable.
Umbilical cord blood mononuclear cells (CBMC)
Fresh umbilical cord blood was obtained from placentae as soon as possible
after delivery, with the permission of the mothers. Cells prepared from umbilical cord
blood by the above method were heavily contaminated with red cells. Therefore,
heparinised cord blood was first depleted of erythrocytes by adding 2 ml 1% w/v
methylcellulose (Sigma) in PBS to each 10 ml aliquot, mixing for 15 min. at 37 °C,
then diluting with an equal volume of PBS and allowing erythrocytes to sediment for
30 min. The leucocyte-rich supernatant was then subjected to density gradient
centrifugation as described for PBMC.
Sheep erythrocyte rosettes
Preparation of sheep red blood cells (SRBC). Sheep blood was collected into an
equal volume of Alsever's solution and washed three times with sterile PBS, each
time centrifuging at 400 x g for 15 min. at 20 °C and removing any buffy coat.
Packed cells were pipetted into 2-aminoethylisothiouronium bromide hydrobromide
solution241 (AET; see Appendix I) (Sigma), incubated for 30 min. at 37 °C and
washed three times as before. The erythrocytes were then resuspended at 4% v/v in
sterile PBS and stored at 4 °C until required.
Rosetting procedure. Rosetting was performed on PBMC obtained as described
above. Using 2.5 ml of the 4% SRBC suspension for each 10 ml of the original blood
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sample from which the PBMC were obtained, the erythrocytes were washed once
more, as described above, just before use. The PBMC suspension was added and the
mixture centrifuged gently at 223 x g (1,000 rpm) for 5 min. at 20 °C to enhance
rosette formation. The cells were then resuspended and separated over Lymphoprep.
Non-rosetting (E~) cells. Buoyant, non-rosetting mononuclear cells were aspirated
from the top of the density gradient and washed once with sterile PBS, centrifuging
at 322 x g (1,200 rpm) for 12.5 min. at 20 °C. Erythrocyte lysing buffer (see
Appendix I) was added to the resuspended cells, and, after mixing for 1 min., an
excess of sterile PBS was added. Following centrifugation at 322 x g for 10 min. at
20 °C, the E~ cells were resuspended in complete culture medium before counting.
This preparation was used as a source of antigen-presenting cells (APC).
Rosetting (E+) cells. After removal of E~ cells, the supernatant and density gradient
were aspirated and discarded. The rosetted cells were then resuspended and washed
once with sterile PBS, centrifuging at 322 x g for 10 min. at 20 °C. The cells were
again resuspended and the density gradient separation step repeated. After a further
wash, the rosettes were treated with lysing buffer, washed and counted, as for E~
cells. The E+ cells thus obtained were used as a source of T-lymphocytes.
Removal of adherent cells
For some experiments, E+ cells were further depleted of antigen-presenting
cells by adherence of the latter to plastic surfaces. Cells were incubated for 1 hour
at 37 °C, either in a small volume (~5 ml) in a sterile Petri dish or in a loosely
packed nylon wool column, in the barrel of a 10 ml syringe. In each case, non¬
adherent cells were eluted with RPMI before washing and resuspending in complete
62.
culture medium.
CD4+ and CD8+ T-cells
T-lymphocytes expressing the CD4 or CD8 co-receptor molecules were
obtained by sequential positive selection using paramagnetic beads bearing covalently
linked surface mouse IgM monoclonal antibodies directed against specific epitopes
on the target molecules.
E+ cells obtained from 80 ml blood, and 250 pi Dynabead-M450-CD4
(Dynal 111.15) were washed separately with sterile PBS containing 5% v/v fetal calf
serum (PBS/FCS). After discarding the supernatants, the beads were resuspended in
~200 pi PBS/FCS and added to the cell pellet, with thorough mixing. Following
incubation for 30 min. at room temperature, with intermittent mixing, 10 ml
PBS/FCS were added and the tube was placed in the magnetic separator for 2 min.
The supernatant, containing unbound cells, was poured off and subjected to two
further depletions of magnetic particles to remove all CD4 beads. Similarly, the
beads, with their bound cells, were washed twice to remove contaminating unbound
cells and then resuspended in a small volume (~50 pi) of PBS/FCS. Cells were
released from the Dynabeads by adding 20pl DETACHaBEAD (Dynal 125.03),
containing goat or sheep poyclonal antibodies specific for mouse Fab epitopes, and
incubating for 30 min. at room temperature, with intermittent mixing. Finally, the
beads were removed from the detached cells by means of three depletions with the
magnet, following which the cells were centrifuged and resuspended in complete
culture medium.
The original supernatant fraction from the above was then processed in an
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identical manner with Dynabead-M450-CD8 (Dynal 111.07).
CD45RO+ and CD45RA+ T-cells
Subpopulations of T-lymphocytes expressing the RO and RA isotypes of the
CD45 molecule were prepared by negative selection of CD4+ cells, obtained as
described above, using Dynabeads in an indirect method.
Two aliquots of CD4+ cells, each containing ~20 x 106 cells, were centrifuged
at 322 x g for 6 min. and the supernatant removed. The cells were then incubated for
30 min. at 4 °C in the presence of 20 pi of mouse anti-human CD45RO or mouse
anti-human CD45RA (Dako) monoclonal antibody. After three washes in PBS/FCS,
to remove excess antibody, 250 pi of Dynabeads (Dynal 110.05), coated with a
primary goat antibody specific for the Fc region of mouse immunoglobulin, were
added to each tube, followed by a further incubation for 30 min. at 4 °C. Unbound
cells were then subjected to three depletions of magnetic particles and bound cells,
washed and suspended in complete culture medium.
Flow cytometric analysis of cell populations
Surface phenotyping of cells was performed on a Coulter XL flow cytometer
equipped for three-colour analysis. Data were saved in listmode fdes and analysed
using WinMDI wersion 2.1.4.
When staining cells, ~2 x 105 cells were used for each antibody or
combination of antibodies. Cells were washed once with PBS/FCS and centrifuged
at 322 x g for 6 min. After removing the supernatant, 5 pi of the relevant antibody
preparation(s) were added and mixed well with the cells, which were then incubated
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for 30 min. at room temperature. Following a further wash, the cells were
resuspended in 1 ml PBS/FCS, and 1 ml 2% w/v paraformaldehyde in PBS was then
added. Tubes were kept at 4 °C until analysed.
All staining was direct, and the antibody-fluorochrome conjugates used are





























































All cultures were maintained in 'complete culture medium'. RPMI 1640
medium (Flow or Gibco) containing 25 mM HEPES buffer was purchased without
L-glutamine or bicarbonate. To each 100 ml were added 3 ml 7.5% w/v NaHC03
solution (Sigma or Gibco); 12 ml heat-inactivated (56 °C for 30 min.), sterile-filtered
(0.22 pm), human AB serum; 2 ml L-glutamine 200 mM (Gibco) and 2 ml of a
solution containing penicillin 5,000 iu/ml plus streptomycin 5,000 pg/ml (Gibco).
Antigens and mitogens
Sacc. An aqueous extract of dried baker's yeast was prepared as previously
described.
Purifiedprotein derivative ofMycobacterium tuberculosis (PPD). This was obtained
as a pharmaceutical preparation containing 100,000 u/ml tuberculin (Evans Medical).
Tetanus toxoid (TT). Unadsorbed tetanus vaccine, 60 ml (Evans Medical) was
dialysed extensively against distilled water, sterile filtered (0.22 pm) and lyophilised.
It was then redissolved in 10 ml distilled water, centrifuged and re-filtered.
Streptokinase/streptodornase (SK). 20 ml of distilled water were added to a vial of
Varidase Topical (Lederle Laboratories), according to the manufacturer's instructions.
Pokeweed mitogen (PWM). A stock solution of 2 mg/ml was prepared by dissolving
10 mg lyophilised lectin from Phytolacca americana (Sigma) in 5 ml sterile water.
Phytohaemagglutinin (PHA). A stock solution of 400 pg/ml was prepared by
dissolving 2 mg lyophilised lectin from Phaseolus vulgaris (Murex) in 5 ml sterile
water.
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Interleukin-2 (IL-2). A stock solution of 104 u/ml was prepared as a l/io dilution of
purified lymphoblastoid IL-2 (Biotest) in RPMI 1640. Preliminary experiments were
conducted to assess the activity of this preparation (see Appendix II).
All of the above were stored at —20 to —30 °C until required.
Proliferation assays
For experiments using PBMC or CBMC as responder cells, cells were adjusted
to 2/3 x 106/ml in culture medium and deposited into sterile 96-well, U-bottomed
culture plates (Costar or Flow) at 105 cells in 150 pl/well. Dilutions of
antigens/mitogens were prepared in culture medium at four times their intended final
concentrations in culture and added to the wells in 50 pi volumes; the same volume
of culture medium alone was added to control wells. The number of replicate wells
varied between experiments. Plates were then placed in a 37 °C incubator with a
humidified atmosphere containing 5% C02.
On the day of harvesting, the cells were pulsed with 1 pCi of [methyl-3H]-
thymidine ([3H]-Tdr) (Amersham) by adding 1 pi of a 1 mCi/ml solution to each well
and incubating for a further six hours. The cells were then harvested on to glass fibre
filters using a semi-automatic cell harvester (Flow). The filters were allowed to dry
overnight prior to (I-counting of the individual discs in 2 ml OptiScint 'Hi Safe'
liquid scintillant (LKB), using a 2 minute counting protocol. For some experiments,
a Topcount system (Hewlett-Packard) was used, which allowed whole plates to be
harvested in a single manoeuvre and counted in the 96-well format.
Median counts per minute (c.p.m.) were calculated for each group of replicate
wells. Results were expressed either as absolute c.p.m. or as the stimulation index:
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g j _ median c.p.m. for stimulated cultures
median c.p.m. for unstimulated cultures
For proliferation assays in which the responder cells were separated T-cells,
lines or clones, the responder cells were incubated in the presence of irradiated
PBMC or E~ cells. A preliminary experiment was conducted to assess the efficacy
of irradiation in preventing thymidine uptake (see Appendix III).
T-cell lines and clones
PHA-stimulated clones. PBMC obtained from a single donor were cloned by limiting
dilution as follows: viable cells were cultured at 0.1 lymphocyte/well in the presence
of PHA 1 p.g/ml, IL-2 50 u/ml and irradiated PBMC at 5 x 104/well in 96-well
culture plates. After 14 days, wells which demonstrated growth were expanded into
flasks containing 15 ml culture medium, IL-2 50 u/ml and irradiated cells at
3 x 105/ml. The medium was replaced after a further seven days, and the cells were
harvested three days later {i.e., ten days after the last addition of feeder cells).
Sacc-specific lines and clones. PBMC from the same donor as above were cultured
at 105/well in the presence of sacc at VlO the concentration which produced maximal
stimulation (this resulted in approximately half-maximal [3H]-Tdr uptake when
assessed at 7 days). On day 5, IL-2 was added at 10 u/ml. Thereafter, the cells were
expanded into culture tubes and then flasks, with repeated rounds of stimulation with
sacc, IL-2 and irradiated syngeneic E~ cells.
From this cell line, after approximately six rounds of stimulation, cloning was
performed by limiting dilution: responder cells were cultured at 1, 3 and 10/well in
the presence of sacc, IL-2 and irradiated E~ cells at 2 x 104/well. Wells which
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showed growth were then expanded as above.
Limiting dilution analysis of precursor cell frequency
A variable number of E+ responder cells was cultured in the presence of
2 x 104 irradiated E~ cells in multiple replicate wells. At each responder cell input,
half of the replicate wells were unstimulated and half stimulated with the antigen
under investigation. After six days, the cultures were pulsed with [3H]-Tdr, harvested
and P-counted. Stimulated wells giving a count greater than the mean + 3 SD of the
counts from the corresponding unstimulated wells were considered to have shown a
positive response.
Results were analysed using the GLIM program (Royal Statistical Society),
which calculates precursor frequency by a maximum likelihood method, and deviation
from single-hit kinetics by a x2 test of goodness-of-fit.
Cell-mediated cytotoxicity assay
Effector cells. PBMC were cultured in bulk at 5x10s lymphocytes/ml in 50 ml
flasks. Four cultures were established for each donor, as follows: unstimulated cells,
cells plus sacc, cells plus PPD and cells plus IL-2. After seven days, the cells were
washed in RPMI supplemented with 10% FCS, resuspended in a small volume of
medium, and a viable count performed. Finally, the cells were adjusted to 5 x 105/ml.
Target cells. Two cell lines were used: mel-1, an NK-resistant line derived from a
malignant melanoma;242 and molt-4, an NK-sensitive line of T-cell leukaemia origin243
(these were kindly provided by Dr. Steve Christmas). These were harvested from
culture, washed twice in RPMI/10% FCS and resuspended in the presence of 10 pi
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of a 10 mCi/ml solution of 51Cr-sodium chromate (Flow). After incubation for one
hour at 37 °C, the cells were washed twice in RPMI/10% FCS and adjusted to
5 x 104/ml after performing a viability count.
The assay was performed in triplicate, by adding 150 pi of each effector cell
suspension to the same volume of each target cell suspension in 11 mm diameter LP3
tubes, to give an effector to target cell ratio of 10:1. After gentle centrifugation at
1,000 rpm (223 x g) for 5 min., followed by incubation for four hours at 37 °C,
150 pi of supernatant were carefully removed from each tube without disturbing the
cell pellet. Respective pairs of pellets and supernatants were then counted in a y-
counter. Fractional release for each pair of tubes was calculated as:
D _ c.p.m. of supernatantK —
c.p.m. of supernatant + c.p.m. of pellet
Spontaneous release was calculated from tubes containing target cells plus 150 pi
medium only, and maximum release from tubes containing target cells plus 150 pi
2% Triton 100 (BDH) to lyse the cells. A mean background count was subtracted
from each experimental count, and the % cytotoxicity for each pair of tubes
calculated as:
R — R




Rtest = fractional release in test sample
Rspon, = mean spontaneous fractional release
Rmax = mean maximum fractional release
The mean of each triplicate was taken as the final result.
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Sacc-speciflc cellular response in Crohn's disease
Subjects
Blood was collected from 20 patients with Crohn's disease and 26 laboratory
staff, who acted as controls.
Of the Crohn's disease patients, 6 were male and 14 female. The median age
was 40 years (range: 18-66 years) and the median (95% CI) disease duration was 11
years (5.2-16.8 years). Small bowel disease (with or without large bowel disease) was
present in 14, and 6 had large bowel disease only. Steroids were the sole treatment
in 2 patients, 5-ASA derivatives in 6, and 4 patients were taking both medications.
None of these patients had been included in the antibody study described in Part I.
Of the control subjects, 11 were male and 15 female. The median age was 36
years (range: 24-49 years).
PBMC were separated as described and serum was stored. Proliferation assays
were carried out with PBMC from each subject to assess the response to sacc, SK,
TT and PPD. Cultures, in replicates of six, were harvested at 6 days. Serum IgG anti-
sacc was measured in all subjects, and AAG in the Crohn's disease group.
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RESULTS
Response of PBMC to sacc
Dose-dependency
The [3H]-Tdr uptake, after seven days in culture, of PBMC from normal
donors in response to four-fold dilutions of sacc, PPD and PWM is shown in Fig. 8
& 9. No subject failed to respond to sacc or PPD, although it can be seen that the
response varied considerably between individuals, especially when the stimulus was
sub-maximal. Even when only the maximum Sis achieved by each subject were
considered (i.e. regardless of dose), the response was still highly variable (Table 9).
An optimal response to sacc appears to be more critically dependent on dose
than is the case for PPD and PWM, which both produce a shallow plateau of
responses over a greater than 200-fold concentration range (Fig. 9). However, this
observation is probably an artefact consequent on excessive dilution of the culture
medium when larger amounts of the sacc solution were added.
Stimulus Median S.I. 95% C.I. Range
sacc 84 47.4-203.1 7.8-617
PPD 154.5 75.8-315.4 7.9-1007
Table 9. Maximum stimulation indices in response to sacc and PPD in healthy subjects.
Time course
Data on the time-course of the proliferative responses were obtained by
measuring [3H]-Tdr incorporation daily in the presence of the concentration of sacc,
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PPD (as total protein, pg/ml)
PWM (fjg/ml)
Figure 8. Dose-response ofPBMCfrom normal subjects to sacc, PPD and PWM. Individual data are
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Figure 9. Dose-response of PBMC from normal subjects to sacc, PPD and PWM. Data shown in
Fig. 8 have been condensed to medians and 95% confidence intervals for the sample. Arrows show
concentrations used to assess time course of the response.
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PPD and PWM which had produced the optimal response at seven days. Whereas
PWM elicited very early proliferation which was maintained throughout the course
of the experiment, peak responses to sacc and PPD were delayed at 7 days and 5-6
days respectively (Fig. 10).
Response of CBMC to sacc
CBMC were incubated with concentrations of sacc, PPD, TT, PHA" and
PWM which had been shown to be optimal for adult PBMC. The incubation period
was 4 days for PHA and 7 days for the other stimuli. At the end of this time, the
incorporation of [3H]-Tdr was compared with that of similar cultures of normal adult
PBMC.
When expressed as absolute counts per minute, the background response of
CBMC cultures was significantly higher, and the PPD response significantly lower,
than that of PBMC (Fig. 11a). Although all stimulation indices were significantly
lower for CBMC (Fig. lib), this was probably a consequence of the markedly
elevated background uptake.
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FIGURE 10. Time course of PBMC response to a) sacc, b) PPD, and c) PWM. Medians and 95%






































Sacc PPD TT PWM PHA
FIGURE 11. Response of CBMC (shaded bars) and PBMC (open bars) to sacc, recall antigens and
mitogens, a) counts per minute; b) stimulation indices. Error bars represent 95% confidence intervals
about the median. * = P < 0.05; ** = P < 0.01 (Mann-Whitney).
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Responses of separated cell populations
The responses of separated cells were examined in a healthy subject whose
PBMC had responded to sacc with a SI of >100.
Rosetting and non-rosetting cells
Effectiveness of rosetting. The effectiveness of sheep cell rosetting in separating
T-cells from PBMC is demonstrated in Fig. 12, 13 and Table 10. CD3+ T-cells were
depleted in the non-resetting (E~) population and enriched in the rosetting (E+)
population, with reciprocal changes in CD14+ (monocyte/macrophage) cells and
CD19+ B-cells.
Marker PBMC E" E+ Morphological gate
CD3 72.2 (67.6) 5.6 (2.5) 86.5 (82.7) lymphocyte (all cells)
CD19 7.5 (6.0) 33.3 (14.9) 0.05 (0.05) lymphocyte (all cells)
CD 14 0.43 (5.02) 16.7 (40.4) <0.1 all cells (monocyte)
Table 10. Cell surface markers before and after rosetting. All figures are per cent.
T-cells as responder cells: dependency on APCs. When cells were separated by
rosetting and selectively irradiated, responsiveness to sacc, SK and TT was seen only
when both T-cells and APC were present in culture. The response was abrogated by
irradiation of the T-cells but was maintained if the APC were irradiated. The response
to PHA was less sensitive to depletion of APCs (Fig. 14).
Supplementation of T-cells with increasing numbers of APCs had a dose-
dependent effect on the restoration of responsiveness to sacc (Fig. 15).
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FIGURE 12. Morphology of cells, byflow cytometry, before and after separation by sheep erythrocyte
rosetting: a) PBMC, b) E~, c) E+. In each panel, the main population, at lower left, is oflymphocytes.
The enrichment ofE' cells with monocytes is clearly shown in 'b' as a large population of cells with













Figure 13. Cell surface markers before and after rosetting. Shaded histograms are: a) CD19 on E~
cells, b) CD14 on E~ cells, c) CD3 on E~ cells, d) CD3 on E* cells, and e) CD19 on E+ cells. Outline
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FIGURE 14. Response ofseparated cells to a) PHA, b) sacc, SK and TT. Bars represent medians and
ranges offive replicates. (T — E+ cells at 10s/well, APC = E cells at 2 x 104/well; E* cells were
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CD4+ AND CD8+ CELLS
A preliminary experiment was done, using PBMC from three healthy donors,
to compare the phenotypic characteristics of cells after stimulation with sacc, SK, TT
and PHA, with those of control cells, incubated with culture medium only. In all
cases, sacc, SK and TT lead to a relative rise in the proportion of cells expressing
CD4 and a reciprocal fall in CD8+ cells. The change was particularly marked among
cells with high forward and side scatter (as defined by the gating region R2). By
contrast, in PHA-stimulated cells, any rise in CD4 relative to CD8 expression was
much less marked, and, in one case, this ratio fell (Fig. 16 & 17).
PBMC from one of the above donors were then separated into CD4+ and CD8^
populations, prior to stimulation in the presence of irradiated APC. The separation
was highly efficient, with >97% purity being obtained in each case (Fig. 18). Only
CD4+ responded to sacc, SK and TT, whereas Both CD4+ and CD8+ cells responded
to PHA and PWM (Fig. 19 and Table 11).
CD45RO+ AND CD45RA+ CELLS
CD4+ cells from the above donor were further separated into cells expressing
CD45RO and CD45RA. In each case, >93% purity was achieved (Fig. 20). The
response of CD45RO+ cells to sacc, SK and TT was considerably greater than that
of CD45RA+ cells. By contrast, the response to PWM was greater for the CD45RA"





FIGURE 16. Gating of cells after stimulation. Panels on right are as those on left but showing fewer
events, and with gates superimposed: a) control, b) sacc (the appearance was similarfor SK and TT),







































FIGURE 17. Surface markers of cells after stimulation. R1 and R2 are morphological gates as shown
in Fig. 16. Within these, only CD3* were examined further for CD4 and CD8 expression. Symbols
represent three different donors.
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FIGURE 18. Flow cytometric analysis ofseparated CD4+ and CD8+ T-cells: a) dotplot showing FS/SS
ofcells positively selected on CD4 — region R1 was used as a lymphocyte gate, b) histogram showing
CD3 expression of cells in R1 — marker Ml was used to define a further logical gate for CD3+
lymphocytes, c) dotplot showing CD4 and CD8 expression of cells gated on R1 and Ml — numbers
in each quadrant represent percentages of total events within the gate, d) dotplot analogous to that
in 'c' but obtained with cells positively selected on CD8.
87.
10s T











d6 cont. sacc SK
:2L
TT PWM
figure 19. Response ofCD4+ and CD8+ T-cells to sacc, mitogens and recall antigens. Bars represent
the median and range offive replicate counts.
Stimulus CD4+ CD8+
day 3 control 58 — 62 —
PHA 53,863 (929) 37,168 (599)
day 6 control 157 — 102 —
sacc 18,099 (115) 124 (1.2)
SK/SD 15,166 (97) 104 (1.02)
TT 30,228 (193) 124 (1.2)
PWM 36,754 (234) 16,061 (157)
Table 11. Data from Fig. 19. Numbers are median counts per minute of five replicates, with
stimulation indices in brackets.
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CD45RO-FITC
FIGURE 20. Flow cytometric analysis of CD45RA + and CD45RO+ cells: a) FS/SS of CD4+ cells before
negative selection — region R1 was used as a lymphocyte gate, b) Ml was used to gate CD3+ cells
within Rl, c) distribution ofCD45 isotypes by double staining ofunseparated CD4+ cells, d) CD45RO
expression after depletion of CD45RA+ cells (shaded), e) CD45RA expression after depletion of
CD45RO+ cells (shaded) — in each case, the outlined histogram shows the distribution of the same











control sacc SK TT PWM
FIGURE 21. Response of CD45RA+ and CD45RO+ cells to sacc, SK, TT and PWM. Bars represent
median and range offive replicate counts.
Stimulus CD45RA CD45RO
control 294 — 509 —
sacc 8,590 (29.2) 67,730 (133)
SK/SD 714 (2.4) 37,883 (74.4)
TT 2,126 (7.2) 58,722 (115)
PWM 59,294 (202) 34,548 (67.9)
TABLE 12. Data from Fig. 21. Numbers are median counts per minute of five replicates, with




Measurement of the frequency of saec-specific cells in the circulating
population was attempted in one normal donor. A preliminary experiment was
performed, using semilog increments in T-cell (as E+ cells) input, in order to guide
further experiments (Fig. 22a). Three further attempts were then made to measure the
precursor frequency, with various cell inputs and numbers of replicates. However, in
all except the first experiment, x2 analysis suggested that the null hypothesis of
single-hit kinetics should be rejected (Fig. 22b, c & d). Notwithstanding this, the
calculated frequencies were compatible between experiments.
SK-specific precursors
A single experiment to measure SK-specific precursor cell frequency did
conform to single-hit kinetics and gave a result very similar to that for sacc (Fig. 23).
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FIGURE 22. Sacc-specificprecursor cellfrequency. Lines represent the calculatedprecursorfrequency
and its 95% confidence interval. For each plot, the relevant X and associated P values are shown with
the reciprocal precursor frequency and its 95% confidence interval. Forty-eight replicates were used
at each cell input for 'a' and 'b', and sixty for 'c' and 'd'. (In each case, the degrees offreedom are
one fewer than the number of data points.)
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cell input x 10 3
FIGURE 23. SK-specific precursor cellfrequency. Treatment as for Fig. 22. Sixty replicates were used
at each cell input.
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Cytotoxicity of stimulated PBMC
The % cytotoxicity of PBMC, obtained from six normal donors and cultured
in the presence of different stimuli, against the mel-1 and molt-4 cell lines is shown
in Fig. 24. The effector to target cell ratio of the data shown was 10:1 (similar results
were obtained for ratios of 20:1 and 5:1 but these data were less complete). All
stimulated effector cells demonstrated significantly greater cytotoxicity against each
of the target cell lines than did the unstimulated control cells (P < 0.05 in all cases;
Wilcoxon signed rank test). Antigen- and sacc-stimulated cells elicited greater killing
against the NK-sensitive line (molt-4) compared with the NK-resistant line (mel-1).
501
mel-1 molt-4
Figure 24. Cytotoxicity assay. Sacc and PPD were used at the concentrations which gave optimal
stimulation in the proliferation assay; IL-2 was at 50 u/ml. Bars show mean ± SEM.
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T-cell lines and clones
PHA clones
Seven clones grew successfully following stimulation with PHA and IL-2; five
were CD4+ and two CD8+, by flow cytometry. All retained the ability to respond to
the mitogens, PHA and PWM, but, with the exception of one CD8+ clone (JD.R4),
which appeared to show a small response to PPD, none proliferated in response to
sacc or PPD (Fig. 25).
Sacc-specific lines and clones
After repeated rounds of stimulation with sacc, IL-2 and APC in bulk culture,
it was possible to produce a T-cell line which appeared to demonstrate specificity for
sacc.
A single CD4+ clone which also demonstrated sacc-specificity was isolated by
limiting dilution at a frequency of 3 cells/well (Fig. 26).











Figure 25. Proliferation responses ofclones initiated with PHA/IL-2. Clones were cultured at 5,000
cells/well with 10s irradiated PBMC as APC. Points are medians offour replicate counts. Negative
values are a consequence of subtraction of [3H]-Tdr uptake of irradiated PBMC in the absence of
responder cells. 'Sacc' and '2 x sacc' represent protein concentrations of 8.6 and 17.2 /ig/ml.
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Cellular response to sacc in Crohn's disease
As before, IgG anti-sacc was greater in the Crohn's disease group than in the
normal controls (Crohn's: 2.4, 1.10-4.40; normal: 0.71, 0.51-1.04; P = 0.009)
(Fig. 27). These values were lower than in the equivalent groups in the antibody
study described in Part I; however, all of these samples were processed in a single
assay and so would have been equally affected by any systematic error. The mean
serum AAG of the Crohn's group was 1.20 g/1 (1.04—1.37), which was very similar
to that of the larger sample reported previously.
Several significant differences were found between groups when comparing
the sacc-specific proliferative responses at different doses (Fig. 28). Flowever, in view
of the number of comparisons made, these significance values should be interpreted
with caution, and they do not convey a strong impression of a real difference between
the Crohn's disease and normal groups.
There were no significant differences between the two groups (either in
absolute c.p.m. or S.I.) in the proliferative response to any of the concentrations of
























FIGURE 27. IgG anti-sacc in Crohn's disease and normal controls. Data have been log transformed


































sc1 sc2 sc3 sc4 sc5 sc6 sc7 sc8
Figure 28. Proliferative response to sacc in Crohn's disease and normal controls, a) c.p.m., b) S.I.
Bars show 95% confidence intervals about medians of six replicates. SC, represents the optimal




























































































FIGURE 29. Proliferative response to SK, TT and PPD in Crohn's disease (shaded) and normal
controls (open). Bars show 95% confidence intervals about medians of six replicates. SK,, TT, and
PPD are optimal stimulating doses, with semilog dilutions of SK and TT as in Fig. 28.
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Ultrafiltration and gel filtration
A purified high molecular weight fraction was prepared" by subjecting the
aqueous extract to an approximately six-fold volume reduction by ultrafiltration using
a TCF 2 micro-thin-channel ultrafiltration system (Amicon) with membranes having
a 50 kD molecular weight cut-off; the ultrafiltrate was then lyophilised and the re-
dissolved product was applied to a Sepharose CL6B column (Pharmacia) equilibrated
in sterile water. The fraction eluting in the void volume was collected and lyophilised.
This fraction showed a single band of apparent mw = 200 kD after SDS-PAGE and
staining with Coomassie brilliant blue and PAS.
Proliferative response to high molecular weight fraction
PBMC, obtained from four donors who had previously demonstrated
significant proliferative responses to sacc, were tested for their ability to proliferate
a: this preparation was the work of Mrs. S. Allen.
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in response to doubling dilutions of the high molecular weight fraction.
Effect of pronase on sacc
Pronase digestion
A stock solution of sacc was prepared by dissolving the lyophilised
preparation at 100 mg/ml in PBS, centrifuging to remove undissolved material, and
sterile filtering to 0.2 pm.
A stock solution of pronase (Sigma) at 100 mg/ml was prepared by adding
10 ml PBS to a bottle containing 1 g of the enzyme. Further dilutions, with pronase
concentrations of 0.2 and 2 mg/ml, were prepared in PBS.
The following mixtures were prepared in sterile tubes, using equal volumes
of the solutions indicated:
A: sacc + PBS
B: sacc + 0.2 mg/ml pronase
C: sacc + 2.0 mg/ml pronase
D: PBS + 0.2 mg/ml pronase
E: PBS + 2.0 mg/ml pronase
The tubes were incubated at 37 °C for 24 hours, heated in a boiling water bath
for 15 minutes, cooled to room temperature, centrifuged to remove any precipitate,
and the supernatants recovered. These were then mixed as follows, again using equal
volumes throughout:
a: A + PBS
(3: B + PBS
r- C + PBS
105.
5: D + PBS
s: E + PBS
£ A + D
rp A + E
Thus, preparations were derived which contained: sacc which had been
subjected to 'mock' treatment with incubation and heat only (a); sacc treated with
pronase at 0.1 and 1.0 mg/ml before heat-inactivation (P and y, respectively);
incubated, heat-inactivated pronase only (5 and s); and mock-treated sacc to which
incubated, heat-inactivated pronase had been added and r|). Constant dilution
factors were used throughout to ensure the equivalence of the actively treated
preparations and their respective controls.
Measurement of carbohydrate concentration
Carbohydrate concentration, as total monosaccharide, was measured
colorimetrically by the phenol/sulphuric acid method of DuBois.244
Solutions of a-D-glucose and a-D-mannose (Sigma), at 10 mg/ml in distilled
water, were prepared for use as standards, and stored at —30 °C until required. The
assay was performed by making doubling dilutions of the standard solutions and test
preparations, adding 200 pi of each to 200 pi water-saturated phenol, and then
rapidly adding 1 ml concentrated sulphuric acid. The light absorbance of the resulting
solutions was measured at a wavelength of 492 nm (using an ELISA plate-reader to
measure duplicate 200 pi aliquots in 96-well plates), and estimates of the
carbohydrate concentrations of different dilutions of the test solutions were derived
with reference to a titration curve compiled from the standards, the form of the
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calculation being exactly as described for the ELISA techniques previously discussed.
Measurement of protein concentration
Protein concentration was measured colorimetrically by the Bradford reaction
method.245
Solutions of bovine serum albumin (Sigma), at 10 mg/ml in distilled water,
were prepared for use as standards, and stored at —30 °C until required. Coomassie
brilliant blue dye concentrate (BioRad), was diluted 1:4 v/v with distilled water. The
assay was performed by making doubling dilutions of the standard and test solutions,
adding 40 pi of each to 2 ml dye, and allowing 30 minutes for full colour
development. The light absorbance of the resulting solutions was measured relative
to a 'reagent blank' (40 pi distilled water + 2 ml dye), at a wavelength of 595 nm
(using a spectrophotometer and disposable polystyrene cuvettes), and estimates of the
protein concentrations of different dilutions of the test solutions were derived with
reference to a titration curve compiled from the standards, as above.
Proliferation response to pronase digest
PBMC derived from a normal donor (known to be responsive to sacc in this
assay) were used. Serial dilutions of preparations a-q were made in complete culture
medium at dilutions of 1/8, 1/24, 1/80, 1/240, 1/800 and 1/2,400 and 50 pi of each added to
five replicate wells containing 105 cells in 150 pi.




The effect of treatment with pronase on the ability of sacc to inhibit specific
antibody-binding in the quantitative ELISA was assessed.
Serial 3-fold dilutions of preparations a-r| were made in PBS, and 40 pi of
each were then added to 220 pi aliquots of the pooled standard IgG anti-sacc serum,
the latter having been pre-diluted in PBS-Tween such that the final serum dilution,
after addition of the inhibitor, was 1/500; 40 pi of PBS were added to diluted serum
as controls. The test and control samples were incubated for 1 hour at room
temperature and then assayed, in duplicate, for IgG anti-sacc antibody by ELISA.
For each pair of duplicate observations a fractional inhibition was calculated
according to:
test mean - control mean 1/w./
x 100%
control mean
Inhibition curves, showing fractional inhibition as a function of the dilution factor,
were then constructed for each preparation.
Comparison of sacc with mannan preparations
Preparation of 'crude' mannan
A mannan preparation was made according to Sutherland and Wilkinson.246
Dried yeast was suspended in distilled water at 200 g in 1 1, washed three times and
resuspended in 500 ml 0.05 M citrate buffer, pH 7. After heating in a boiling water
bath for 1-2 hours and allowing to cool, the suspension was centrifuged at 104 x g
for 15 min. and the supernatant retained. Following the addition of 25 ml glacial
acetic acid, centrifugation was repeated to remove the resulting precipitate and the
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supernatant was neutralised with 6 M NaOH. Mannan was then precipitated and
washed by adding 1 1 ethanol at —40 °C and collecting in a Buchner funnel.
Purified mannan
Purified mannan, prepared from S. cerevisiae by the cetavlon method, was
obtained from a commercial source (Sigma).
Solutions of sacc, crude mannan and purified mannan were prepared in
distilled water at 100 mg/ml, filtered, and stored at —30 °C. Carbohydrate and




High molecular weight fraction of sacc
Proliferative response
Cells from all of the donors demonstrated a proliferative responses to this
preparation after 6, 7 or 8 days in culture (Fig 30).
Pronase digestion of sacc
Effect on protein and carbohydrate content
The titration curves obtained from the carbohydrate and protein standards are
shown in Fig. 31 & 32, respectively. Also plotted are the absorbance values obtained
from the pronase-treated and control preparations. Results calculated from these data
are given in Table 13 & 14, respectively.
Active treatment with pronase did not differ from control treatments in its
effect on carbohydrate content, which was ~8.4 mg/ml (equivalent to 33.6 mg/ml in
the original stock solution of sacc) in all the preparations containing sacc, except that
treated with 1.0 mg/ml pronase, in which the calculated mean concentration may have
been unduly influenced by a single 'outlier' (Fig. 31 & Table 13).
In the protein assay, sacc behaved differently from the bovine serum albumin
standard, giving a titration curve which was markedly non-parallel to the standard
curve. However, active treatment with pronase, at both 0.1 and 1.0 mg/ml, reduced
the protein content to below the minimum which the assay could detect (-250 pg/ml),
whereas the control-treated preparations gave titrations which were identical to each
other, resulting in estimated protein concentrations of 1.16-2.01 mg/ml (equivalent
to 4.65-8.03 mg/ml in the stock sacc solution) (Fig. 32 & Table 14).
110.
10'
conl. .488 .977 1.95 391 7.61 15.6 31.3 62.5 125 250 500 1000
Final conc. of lyophilised product (pg/ml)
FIGURE 30. Proliferative response to high molecular weightfraction ofsacc. Data points are medians












o = mannose standard
• = sacc + mock treatment
■ = sacc + 0.1 mg/ml pronase
A = sacc + 1.0 mg/ml pronase
* = sacc + 0.1 mg/ml inactivated pronase
• = sacc + 1.0 mg/ml inactivated pronase
4 8 16 32 64
reciprocal dilution
128 256
Figure 31. Effect ofpronase and control treatments on carbohydrate content ofsacc. The dashed lines
delineate the portion of the standard titration curve used to calculate results. Carbohydrate was not
detected in preparations containing inactivated pronase alone (not shown).




concentration at which concentration
Preparation (mg/ml) measured (mg/ml)
sacc + mock treatment 9.02 1/8
7.20 1/16 8.4
8.98 1/32






























Table 13. Effect of pronase and control treatments on carbohydrate content of sacc. The
concentrations have been derivedfrom the data shown in Fig. 31.
a: this concentration is derived from a point which appears to be an outlier in Fig. 31. Its exclusion results in a mean












o = BSA standard
• = mock treated sacc;
sacc + inactivated pronase
(superimposed)




Figure 32. Effect of pronase and control treatments on protein content of sacc. The dashed line























TABLE 14. Protein content of sacc subjected to control treatments. The concentrations have been
derived from the data shown in Fig. 32. The data shown are for mock treatment, but those for the
other control treatments are indistinguishable.
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Effect on proliferation response
The effect of pronase digestion on the sacc-dependent lymphoproliferative
response is shown in Fig. 33.
Treatment with 1.0 mg/ml pronase completely abolished thymidine uptake by
peripheral blood lymphocytes, although some proliferation was still evident with
0.1 mg/ml pronase (Fig. 33a). Treatment with inactivated pronase demonstrated no
clear effect (Fig. 33b) and there was no proliferative response to the heat-inactivated
enzyme alone (Fig. 33c).
Effect on ELISA inhibition
The results of the ELISA inhibition assay are shown in Fig. 34.
There was an approximate two-fold concentration difference between the
inhibition curves obtained with actively treated sacc and that obtained with mock
treated sacc. However, a similar result was obtained with sacc to which 1.0 mg/ml
inactivated pronase had been added. Therefore, the observed effect is likely to be due
either to experimental variation or an effect of the pronase protein independent of its
enzymatic activity. In any case, the effect was much less than that seen in the ability
of pronase treatment to abrogate the T-cell response to sacc. No inhibition was
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Figure 33. Effect ofpronase treatment on the lymphocyte proliferation response to sacc. Data points
are the medians offive replicates and error bars show ranges (for clarity, these are omittedfrom two
of the data sets in 'b').
o = sacc + mock treatment
4 = sacc + 0.1 mg/ml
inactivated pronase














o = sacc + mock treatment
□ = sacc + 0.1 mg/ml pronase
A = sacc + 1.0 mg/ml pronase












o = sacc + mock treatment
o = sacc + 0.1 mg/ml inactivated
pronase
★ = sacc + 1.0 mg/ml inactivated
pronase















Figure 34. ELISA inhibition by pronase-treated sacc. The ability of mock-treated sacc in the fluid
phase to competefor antibody binding with sacc on the solid phase is compared with that of a) sacc
treated with active pronase, b) sacc treated with inactivated pronase, c) inactivated pronase alone.
o = sacc + mock treatment
o = 0.1 mg/ml inactivated
pronase alone
V = 1.0 mg/ml inactivated
pronase alone
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Comparison of sacc with mannan preparations
Protein and carbohydrate analysis
The titration curves obtained in the protein and carbohydrate assays of these
preparations are shown in Fig. 35 & 36, and the data calculated from these in
Table 15. In the case of the purified mannan, virtually all of the dissolved material
was accounted for as carbohydrate. However, in the case of sacc and the crude
mannan, a considerable proportion of the original material was unaccounted for —
an observation explained by the fact that when the solutions of these preparations
were made, it was noted that visible amounts of undissolved material were invariably
present; therefore, the actual final concentration of total solute would have been less
than the 100 mg/ml intended. Nevertheless, the ratio of protein to carbohydrate in the
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FIGURE 35. Carbohydrate assay of sacc and mannans. Test solutions were at J 00 mg/ml and the
standard at 10 mg/ml.
o = mannose standard
• = sacc
■ = crude mannan











o = BSA standard
• = sacc
■ = crude mannan
A = purified mannan
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TABLE15.Proteinandcarbohydrateo te tfsaccma nans.D rderiv dfr mFig3&6
Lymphocyte proliferation
The PBMC response to the crude mannan was inferior to that of sacc at an
equivalent dilution (Fig. 37). However, if the dilution factor of the crude mannan is
corrected for protein content relative to sacc, and the response re-plotted, it
approaches that obtained with sacc (Fig. 37, inset) {Note: correction for protein was
based on the relative displacement of the curves obtained with sacc and crude
mannan, without reference to the BSA standard curve}. There was no detectable
uptake of [3H]-Tdr in response to the purified mannan.
ELISA inhibition
The crude mannan elicited a similar degree of inhibition to sacc in this assay.
The relationship was even closer when the dilution factor of the crude mannan was
corrected for carbohydrate content relative to sacc, and the inhibition curves re-plotted
(Fig. 38 and inset).
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• = sacc
■ = crude mannan
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FIGURE 37. Proliferative response to sacc and mannans. Data points are medians offive replicates.




■ = crude mannan
± = purified mannan
Figure 38. ELISA inhibition with sacc and mannans. Data points are means of duplicates. Inset:




Antibodies to sacc in gastrointestinal disease
Because previous studies of antibodies to S. cerevisiae in inflammatory bowel
disease all used sub-optimal methods of internal standardisation and/or quantitation,
I have attempted to develop fully quantitative, isotype-specific ELISAs, using an
aqueous extract of yeast as the antigen. By screening a number of sera, it was
possible to find examples with high antibody-binding, which were suitable for pooling
together to provide standard calibrants. A 'control' assay, for measuring IgG anti-
casein, was developed in parallel. The assays thus derived all had very low intra-assay
variation, and the inter-assay coefficient of variation was less than 10%, except in the
case of the IgG anti-sacc ELISA, where a storage artefact may have resulted in an
erroneously high estimate of 15-19%.
I wished to determine whether the results of previous studies could be
reproduced with this assay. In addition, it was desirable to obtain further information
on the influence of site and activity of Crohn's disease on antibody levels, since this
has either been omitted from earlier reports, or data have been conflicting.
Although the different groups in this study were not matched for age and sex
distribution, and there was a significant bias towards males amongst healthy subjects,
the antibody results in this group were not dependent on either of these variables. The
median value of IgG anti-sacc in patients with Crohn's disease was over three times
that in healthy subjects. A smaller increase was seen in patients with chronic liver
disease of various aetiologies. The latter group was included in this study because
there was pre-existing evidence of enhanced antibody responses to other dietary
125.
antigens in liver disease (see p. 13); it was therefore felt that these patients would be
a valuable control group, when assessing whether enhanced systemic immune
responsiveness to yeast was specific for Crohn's disease.
The results for IgA show that only partial success was achieved in respect of
the aim of obtaining fully quantitative results with the antibody assays. This was
because specific IgA was unmeasurably low in a large proportion of samples from all
of the groups tested — only 20% of sera from normal subjects could be quantified
for IgA anti-sacc; even among sera from Crohn's disease patients (who had the
highest proportion of quantifiable sera), only 55% could be quantified. It may have
been possible to 'push' the assay by using lower dilutions of the test sera, but this
was avoided for technical reasons.152 Therefore, IgA results were analysed after
classification as 'positive' or 'negative'. The threshold level chosen as the basis for
this classification was the 95th. centile of the values obtained from normal sera, the
rationale for the choice being that this would result in an acceptably low number of
'false positives' if the assay were to be used as a diagnostic test, as well as allowing
a reasonably robust test of significance. IgA anti-sacc was positive in one third of
Crohn's disease patients," this frequency being over six times that in normal subjects.
In patients with liver disease, there was also an increased frequency ofpositive results
for IgA, but the P value achieved in this case was not sufficiently low for the
difference to remain significant after taking into account the number of comparisons.
Among patients with Crohn's disease, there was a strong trend towards higher
levels of IgG anti-sacc in those with small bowel disease (with or without large bowel
disease) compared to those without small bowel disease, but this did not quite achieve
a: applying a similar analysis to IgG anti-sacc gave a result of-45%
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significance. IgA anti-sacc correlated with duration of disease, when the actual
numerical value of the former was taken into account, and IgG anti-sacc was higher
in patients in whom the serum AAG was above the normal range.
These results confirm that the humoral response to S. cerevisiae is enhanced
in Crohn's disease, but they also show that the finding is not confined to this group,
being also a feature of chronic liver disease. The absence of an increased response in
subjects with coeliac disease was not unexpected, since all were on a gluten-free diet
and evidence suggests that antibodies to non-gluten dietary antigens may decline
under these conditions (see p. 12, 13). The results also suggest, but do not establish,
a relationship between antibodies to sacc and disease of the small bowel, active
disease and disease of longer duration. It is important to note, however, that the
Crohn's disease group consisted virtually exclusively of outpatients with relatively
well-controlled disease (median AAG of 1.1 g/1 and median Bristol Activity Index
score 1.5). Therefore, the power of the study to detect any effect due to this variable
will have been low. Furthermore, in the majority of cases, the symptoms and/or
diagnosis had been established for several years (median duration 7 years), and so no
information is available pertaining to antibody levels at or near the time of onset of
disease. A prospective study would be a suitable way of investigating whether
antibody measurements made as early as possible after presentation might have any
predictive value in diagnosis.
There is clearly a question to be asked concerning the mechanism of the
increased antibody response in Crohn's disease. It is not possible to say whether the
production of anti-sacc antibodies reflects an immune response which is generated
following sensitisation of cells of the gastrointestinal lymphoid system per se, or
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whether it represents a systemic response to antigen which has 'bypassed' the normal
handling mechanisms of the gut and gained access to the systemic circulation.
However, activation of lamina propria T-cells is evident in active Crohn's lesions,247
and it is conceivable that at least some of these are recognising peptide products of
luminal antigens. Furthermore, Peyer's patches, which are specialised sites for
sampling and processing antigen, are predominantly localised in the small bowel,248
which could explain an association of the antibody response with disease at this site,
were one to be confirmed. Conversely, evidence has been available for many years
that intact protein can be absorbed from normal mucosal surfaces in sufficient
quantities as to be biologically significant, as demonstrated experimentally by the
phenomenon of passive cutaneous anaphylaxis,249 and clinically by systemic
anaphylaxis to foods in sensitised subjects.
Neither the Crohn's disease nor liver disease group differed from
healthy subjects with respect to IgG anti-casein. This protein was chosen as a control
antigen because Barnes et al.19 found that the majority of sera with anti-milk
antibodies reacted with it, although other studies have more frequently found
antibodies to other milk proteins (see p. 6 ff). In any case, the choice was effective
since a wide range of binding activities could readily be detected and quantified in
normal and pathological samples. It is therefore interesting to speculate that the
enhanced antibody response to S. cerevisiae in Crohn's disease may be dependent on
peculiarities of its antigenic structure.
Finally, it should be borne in mind that no inference can be taken from these
data as to the biological significance of anti-sacc antibodies, nor concerning any
possible aetiological role of bakers' yeast in Crohn's disease. Although it is well-
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established that the condition responds to therapeutic strategies based on replacement
of the normal diet by various liquid feeds,250 and, in one study, yeast was identified
subjectively by patients as having contributed to symptomatic deterioration,251 there
is only one published investigation of the effect of yeast exclusion on disease activity.
Barclay et al.252 used a Crohn's disease activity index (CDAI) to monitor the progress
of 19 patients who were in clinical remission at the start of the study. Following a
baseline observation period, all patients ate a low-yeast diet to which placebo and
yeast capsules were added (these were given sequentially and the order was
randomised). The mean CDAI was higher during the yeast inclusion period than the
yeast exclusion period. This was also true for the maximum CDAI, which was also
lower during the yeast exclusion period than the baseline period. However, the
differences, though significant, were very small.
Thus, although this study adds to the evidence that Crohn's disease patients
are predisposed to increased antibody responses to some dietary antigens, there is
currently no reason to presume that this is other than an epiphenomenon of the
disease process.
Cellular responses to sacc
In this study, a proliferative response of PBMC to sacc was universally
detectable in all healthy subjects. The magnitude of the response, however, was very
variable between individuals. In this respect, it was similar to the response to the
recall antigen PPD. In addition, maximal in vitro responses to the optimal stimulating
concentrations of sacc and PPD occurred after about one week in culture; this was in
contrast with the earlier response to the polyclonal mitogen, PWM. Maximal tritiated
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thymidine uptake due to PHA also occurs early, at about day 3 (not shown).
In order to characterise the immunological response to sacc, it was important
to establish whether it was acting as a true antigen or as a non-specific lymphocyte
activator. My first approach to this problem was to test whether sacc could induce
proliferation in cord blood lymphocytes. Cord blood contains immature lymphocytes
which have been said to be relatively unresponsive to various stimuli.253 With respect
to Candida mannan, a negative response of CBMC in one study has been claimed as
evidence for antigen-specificity,145 whereas a positive response in another was
considered to be evidence for mitogenicity.254 Similarly, mitogenicity was inferred
from CBMC responsiveness to a cell wall/membrane preparation from Cryptococcus
neoformans.255 I found the most striking feature of CBMC to be a very high rate of
thymidine uptake in the absence of any stimulus. This observation, which has been
made by some authors153,253 but not others256 is likely to have had a profound effect
on the Sis, since the denominator in the calculation is necessarily large. Some authors
have quoted only Sis as measures of CBMC responses,255 but this study clearly shows
that uncritical acceptance of this derived variable could be problematic. In fact, visual
inspection of the cultures suggested that only PHA and PWM resulted in true
proliferation, suggesting that the high background counts in these cells may relate to
'redundant' DNA synthesis uncoupled to proliferation per se. In any case, the
contention that CBMC do not contain cells capable of antigen-specific responses is
not unassailable, since cells responding to hsp 65 have been reported to be present at
a precursor frequency similar to that in adult PBMC, and PPD-specific precursors at
a frequency of as high as 1/6,000.222 Furthermore, MHC class II-dependent CBMC
responses to PPD and Paracoccidioides brasiliensis have been reported,256 and CBMC
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responses to dietary antigens has been claimed to predict the development of future
allergy.257'258
Stronger evidence of antigen-specificity came from experiments using purified
cell populations. In the first of these, T-cells were isolated by sheep cell rosetting and
further depleted of adherent cells; non-rosetting cells were used as APC or accessory
cells. T-cells depleted of APC were profoundly unresponsive to sacc and the recall
antigens SK and TT. The response to PHA was less sensitive to depletion of
accessory cells (the fact that some stimulation was still detected implies that the 'T-
cell' preparation still contained some accessory cells, since a pure T-cell population
cannot respond even to PHA259). Furthermore, responsiveness to sacc was restored
incrementally by the addition of increasing numbers of APC. All responses were
abrogated by irradiation of the T-cell fraction, but not the APCs, confirming that the
former were the responding cells.
When cells from three healthy donors were incubated with sacc, SK or TT,
there was a rise in the proportion of CD3+ cells expressing the CD4 co-receptor
molecule and a reciprocal fall in CD8+ cells, compared with unstimulated cells or
cells incubated with PHA. These changes were more marked among cells with high
forward- and side-scatter, which are likely to include blasts. A further experiment,
using highly purified CD4+ and CD8+ cells from one of these donors showed that
only CD4+ cells responded to sacc, SK and TT, whereas both populations responded
to PHA.
CD45 (leucocyte common antigen) is a transmembrane tyrosine phosphatase
involved in signal transduction which is expressed in multiple isoforms through
alternative splicing of three exons encoding A-terminal sequences.260 The observation
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that only T-cells expressing the low molecular weight CD45RO isoform have the
capacity to respond to recall antigens and provide help for antibody production led
to the proposal that CD45RO was a marker for the 'memory' cell phenotype. Cells
expressing the high molecular weight CD45RA were thought to be naive, unprimed
T-cells, although they were responsive to mitogens and also appeared to be
alloreactive.261 Although this distinction no longer seems so absolute (CD45RO+ cells
can re-express CD45RA262), the original finding that antigen-specific responsiveness
is largely confined to the CD45RO+ phenotype holds true. Therefore, I sought to
establish how cell populations, selectively depleted of CD45RO+ or CD45RA+ cells,
responded to sacc and other stimuli. Sacc, SK and TT all elicited considerably greater
responses from CD45RO+ cells; by contrast, CD45RA+ cells responded rather better
than CD45RO+ to PWM. It is difficult to say how much of the apparent CD45RA'
response to sacc was due to contaminating CD45RO+ cells, since these could not be
measured flow cytometrically, having been depleted with an antibody identical to the
marker antibody. However, a maximum contamination of 5.9% is possible. If only
CD45RCT cells were responding to sacc, and the response were in proportion to the
number of cells present, this degree of contamination could account for an uptake of
about half of that observed in the 'CD45RA+' population. However, applying the
same principle to SK and TT, the observed counts for CD45RA+ cells should have
been larger, and so sacc did appear to be slightly less selective for CD45RO+ cells in
this single experiment. Of course, the difference may well be within the range of
experimental error, and does not alter the overall impression that sacc-specific
responses bear greater similarity to those to known recall antigens than to polyclonal
mitogens.
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If the cellular response to sacc is antigen-specific, one would expect only a
small proportion of cells in the peripheral blood T-cell population to be capable of
recognising it. Experiments were therefore undertaken with the aim of measuring this
precursor frequency. Unfortunately, although values for the precursor frequency could
readily be derived, in three out of four attempts using cells from the same donor, the
results could not be shown to conform to single-hit kinetics. This could have been
because of inherent variability of the data (see esp. Fig. 22b, p. 92). However, on
inspection of the data plots, there was a suspicion that the fraction of responder wells
at low cell inputs may have been disproportionately low, with data points for cell
inputs <1000/well always lying on the same side of the 95% confidence interval for
the data as a whole." This could mean that the technique as described is insufficiently
sensitive in detecting positive wells with a low number of clonal precursors. This
situation should give a multi-hit curve (concave upwards towards the cell input axis,
on the plots used here);172 this did not seem to be the case visually and the means for
testing this statistically were not available. In any case, re-analysis of the most
complete data set (Fig. 22d), either by omitting the data point from the lowest cell
input, or by taking 2 SD above background as the threshold for a positive response,
gave results compatible with single-hit kinetics. As expected, the first method resulted
in the least alteration to the original estimate of the precursor frequency (an increase
by a factor of 1.07, c.f 1.2 for the second method). The first attempt at measuring
SK-specific precursor frequency gave a result compatible with single-hit kinetics. (It
is worth noting that, paradoxical as it may seem, the more complete the data set, the
more power the analysis has to reject single-hit kinetics, since any observed departure
a: others have also observed this (Dr. X.N. Wang, Newcastle University, personal communication)
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from ideal behaviour is less likely to have arisen by chance.) The frequency estimates
for sacc and SK were very similar. Furthermore, they are in keeping with other
published estimates of frequencies of responder cells to recall antigens.219"222 My
estimate of the sacc-specific cell frequency of Vi,i50 converts to one of 1/600 if only
CD4+ cells are considered, and higher still if only CD45RCL cells participate in the
response. This suggests significant levels of sensitisation to a common dietary antigen
within the circulating T-cell population in at least some healthy subjects. Although
these experiments were not controlled by estimating the precursor frequency to a
mitogen, the ease with which cells could be cloned after stimulation with PHA (see
below) suggested that this was virtually 100%.
Finally, using unselected T-cell clones grown with PHA and IL-2, and lines
and clones grown by multiple rounds of stimulation with sacc and IL-2, it was
possible to show that only cells grown in the presence of sacc responded to it, and
that other recall antigens were ineffective at inducing proliferation in these cells.
However, it must be stated that the cloning efficiency of sacc-specific cells was very
low on limiting dilution — the results presented here represent the only success
among many failed attempts. Furthermore, for unknown reasons, the proliferation
results shown in Fig. 26 could not be reproduced after further rounds of stimulation.
Lines and clones could not be maintained indefinitely because of the regular
requirement for donor-specific APCs, and so further studies were not possible.
That sacc-stimulated cells have enhanced cytotoxicity for NK-sensitive, and
to a lesser extent, NK-resistant target cell lines, suggests that the activity of sacc may
not be confined to effects directly attributable to antigen-specific T-cells. The studies
on which this experiment was based (see p. 27) were designed to examine the ability
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of Candida-derived preparations to act as 'biological response modifiers', with
possible tumoricidal activity, by stimulating MHC-independent cell killing. However,
in the results presented here, cytotoxic activity was possessed to a greater extent by
cells stimulated with PPD, and it seems entirely possible that this in vitro
phenomenon is merely secondary to enhanced NK/LAK cell activity consequent upon
IL-2 release by proliferating antigen-specific T-cells. Unfortunately, no parallel data
on thymidine uptake are available for this experiment, and so it is not possible to
assess the extent to which the cytotoxic response was dependent on the degree of
proliferation in culture. It might be possible to imagine circumstances in which this
stimulation of cytotoxicity might be biologically significant, for example, in inflamed
bowel, but this is highly speculative. Nevertheless, it is interesting to note that
enhanced NK activity on exposure to gliadin has been observed in PBMC from
patients with coeliac disease.263
I did not find convincing evidence for an enhanced cellular response to sacc
among Crohn's disease patients. This is in contrast with the results of Young et al.,2M
who found a mean SI of 15.6 in 12 Crohn's disease patients, compared with 3.3 in
15 healthy subjects after only three days in culture. The antigenic preparation used
by this group was live whole yeast, and nystatin was included in the culture medium.
Otherwise, there is no obvious explanation for the discrepancy between these findings.
Is sacc antigen identical to mannan?
Heelan et al.265 subjected a preparation identical to sacc to sodium dodecyl-
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and found a single band,
under reducing and non-reducing conditions, which migrated with an apparent
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molecular weight of 200 kD and stained weakly with Coomassie blue and strongly
with periodic acid Schiff s reagent — evidence for a high carbohydrate content.
Following transfer to nitrocellulose membrane, immunoblotting with anti-sacc
antibody-positive sera (previously assessed by ELISA) from patients with Crohn's
disease, or hyperimmune rabbit serum, demonstrated binding of antibody to this high
molecular weight band. In addition, binding of rabbit anti-sacc serum was diminished
in a dose-dependent fashion by pre-treatment of the nitrocellulose strips with varying
concentrations of periodate, suggesting that carbohydrate epitopes were essential for
antibody recognition.
On the basis of these findings, and previous work on C. albicans (see p. 27),
a high molecular weight fraction of sacc was prepared by collecting material which
eluted in the void volume of a Sepharose CL6B column. This preparation, termed
'gp 200', which had similar electrophoretic mobility to the band demonstrated by
Heelan et al., stimulated thymidine uptake in PBMC from three different donors who
were selected on the basis of previous responsiveness to sacc. However, it is not
possible to conclude with certainty that gp 200 is the only component of sacc with
this capacity, since lower molecular weight components were not available for testing.
Although gp 200 was not assessed independently for antibody-binding, it seems
reasonable to suppose that it would have shared this characteristic with sacc.
Recently, Young et al.266 carried out a detailed analysis of the antibody-
binding component of sacc. They separated sacc by size-exclusion chromatography
on Sepharose 4B. A fraction of apparent high molecular weight (>200 kD) by SDS-
PAGE — which stained with PAS and, when used as antigenic substrate in an
ELISA, bound antibody from known positive IgG anti-sacc serum — was then
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subjected to further gel filtration on a Superose 6 column, which had been calibrated
with dextrans for more accurate molecular weight determination. A broad peak of
antibody-binding activity was eluted within a molecular weight range of 360-620 kD,
and a mean of MW 460 ± 20 kD was confirmed by size-exclusion
chromatography/multi-angle laser light scattering (SEC/MALLS) on a HPLC system.
This product, termed Sc 500, was found to comprise 90% carbohydrate and 10%
protein by weight (2,790 and 440 residues per molecule, respectively). The
carbohydrate was mannose with a trace of A-acetylglucosamine, with methylation
analysis revealing 1 —>2, 1—>3 and 1—>6 linkages; serine and threonine each
represented over 20% of the amino acid residues of the protein, with asparagine (or
aspartic acid) at 9%, and smaller proportions of other amino acids. Treatment of Sc
500 with periodate or alkaline borohydride reduced its ability to inhibit antibody-
binding in a competitive ELISA with native Sc 500 as primary antigen (IgG- and
IgA-positive human sera and a murine IgM monoclonal antibody, prepared by
immunisation with gp 200,267 were the sources of antibody), whereas pronase, trypsin
and peptide-A-glysosidase F were ineffective. In addition, treatment with a broad-
spectrum a-mannosidase, with activity against 1—>2, 1—>3 and 1—>6 linkages, was
effective at reducing the capacity of Sc 500 to inhibit binding of the monoclonal IgM.
Thus Sc 500 is a high molecular weight species which is similar to gp 200 in three
respects: i) appearance on SDS-PAGE, ii) antigenic cross-reactivity, Hi) dependency
of antibody-binding on carbohydrate structure. Furthermore, it has the composition
expected of cell wall mannan of yeast.
I have made parallel assessments of the effects of protein digestion of sacc on
its ability to compete with native sacc for antibody-binding and on its capacity to
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stimulate proliferation of PBMC. An attempt has also been made to confirm the
effectiveness of the enzymatic degradation by assaying the protein content of sacc
before and after digestion, with the use of appropriate controls to allow for the
presence of inactive enzyme protein. Following protein digestion, antibody-binding
capacity was maintained (in keeping with the results of Young et al., above), but
lymphocyte proliferation was abrogated, and at the higher dose of enzyme, completely
abolished, and this was commensurate with a reduction in measurable protein content.
Therefore, it could be proposed that the B-cell epitopes in sacc are protein-
independent, whereas the T-cell epitopes are (at least) protein-dependent. However,
the first of these conclusions is not entirely safe: because sacc is a mixture, it cannot
be assumed in this experiment that the B- and T-cell epitopes are on the same
molecule; it may be the case, therefore, that B-cell epitopes are present on, for
example, mannan, that these are dependent on intactness of the protein component,
but that the latter is neither measurable by dye-binding, nor accessible to enzymatic
digestion (because of the high degree of glycosylation), while the T-cell epitopes
which are being detected by the in vitro lymphocyte response are present
independently on another protein, which is both measurable and degradable. This
question could only be resolved by testing the effect of protein digestion on the
lymphocyte-stimulating ability of a more pure mannan preparation, such as Sc 500;
to date, this has not been done. Finally, no assessment has been made of the
carbohydrate-dependency of the lymphoproliferative response; it is possible to
envisage, for example, that sugar side chains may participate in binding of the
relevant peptide(s) to MHC class II molecules and/or subsequent T-cell recognition.
Evidence for the participation of sugar residues in MHC-peptide-T-cell interaction has
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been found in a murine model.268
In an attempt to further investigate the possible identity of sacc antigenic
activity with that of mannan, I compared sacc with two different 'mannan'
preparations — a commercial preparation of S. cerevisiae mannan precipitated with
CTAB, and a crude mannan which I prepared according to a published method. Both
methods should result in a relatively undegraded product. When corrections were
made for relative protein and carbohydrate content, the behaviour of sacc and crude
mannan were very similar in both lymphocyte proliferation assays and ELISA
inhibition, respectively. The commercial mannan failed to stimulate PBMC or inhibit
antibody-binding in the sacc-specific ELISA. These last results were unexpected for
two reasons: firstly, CTAB mannan from C. albicans does stimulate PBMC in vitro,
secondly, this preparation of S. cerevisiae mannan was used as antigenic substrate in
an ELISA by Lindberg et al.,5 who found that it behaved very similarly to antigenic
material from whole yeast cells. However, in this study, the protein content of the
commercial mannan was very low (< 0.4% by weight) — although it was said to
have been purified by CTAB precipitation, there is no available information on how
it was extracted from whole cells; since it is possible that it may have been degraded
in the process, this could explain the low protein content and the absence of a T-cell
response. With respect to antibody-binding, the use of two substrates in independent
ELISAs is not equivalent to assessing the ability of one to inhibit antibody-binding
to the other; thus it is conceivable that there are strain-specific differences, or, once
again, differences due to degradation during the production process, between sacc and
the commercial mannan, resulting in poor cross-reactivity. (Since nothing is known
about the T-cell epitopes involved in mannan-specific cellular responses, it is not
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possible to say whether these exhibit strain variation.)
Although it remains the most likely candidate, it cannot be assumed that cell
wall mannan is the only relevant antigen in sacc, with respect to both humoral and
cellular immune responses. Other yeast antigens are certainly capable of being
recognised immunologically. For example, acid phosphatase of C. albicans is a
periplasmic enzyme ofhigh molecular weight (124-136 kD), and also a mannoprotein
(with mannose: protein ratio 7:1). Sera from humans with candidiasis have been
found to contain precipitating antibody to the purified enzyme; antigenic activity, but
not enzyme activity, was heat stable, suggesting that the binding site was on the
glycosidic moiety.269 Acidic carboxyl proteinase is another exocellular manno-enzyme
(mw 45 kD) to which infected humans raise antibodies.270 It is also possible that these
glycoproteins share common antibody-binding motifs with mural mannan. If antibody-
binding by sacc is wholly mannan-dependent, then it should be completely inhibitable
by a highly purified mannan, such as Sc 500; as with the putative T-cell response to
Sc 500, this experiment remains to be performed.
The question arises as to whether the demonstration of anti-sacc antibodies
could represent a secondary phenomenon due to a response initiated by some other,
cross-reacting, antigenic stimulus. Cross-reactivity between yeasts has been
recognised: for example, between A and B serotypes of C. albicans, 131-271-272 and
between C. albicans type B and S. cerevisiae.273 Furthermore, Nnalue et al.214 reported
that one of eight monoclonal antibodies raised against Salmonella thompson, and
which was specific for the O-antigen polysaccharide of serogroup C, Salmonellae,
cross-reacted with 142 of 148 Candida species tested, as well as 4 of 64 strains of
E. coli. However, the fact remains that yeast species and strains are capable of being
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distinguished serologically due to the presence of non-promiscuous determinants.
Furthermore, the question of cross-reactivity was addressed by McKenzie et al.,2'3
who found no difference in Candida-specific antibodies between normal and Crohn's
disease subjects in the presence of highly significant differences for S. cerevisiae.
Moreover, although Barnes et al,4 found an increased prevalence of E. coli antibodies
in Crohn's disease, this was equally the case in ulcerative colitis, whereas prevalence
of anti-sacc was raised only in Crohn's disease. In a recent publication, Sendid et
al.275 have proposed that a mannotetraose structure with an a 1—>3 and two al—>2
linkages is the dominant B-cell epitope responsible for the enhanced antibody
response associated with Crohn's disease. If this is the case, whether or not Crohn's
sera show increased binding activity for antigen derived from a particular yeast
species or strain will depend on its relative expression of this motif. Thus, although
it is possible that the apparent specificity of antibody for S. cerevisiae may have
arisen because of an unrecognised cross-reaction, there is currently no evidence to
support this conclusion.
CONCLUSION. The experimental work presented in this thesis confirms the
observation of enhanced systemic humoral immunity to S. cerevisiae in Crohn's
disease, to the yeast, S. cerevisiae. This was detected using an unfractionated aqueous
extract (sacc), to which in vitro cellular responses are readily detectable in normal
individuals. Different experimental approaches suggest that the cellular response is
antigen-specific, and that the participating cells are CD4+, CD45RO+ T-cells. Evidence
to date supports the hypothesis that the dominant B-cell epitopes in sacc reside on the
yeast cell wall mannan, but the nature of the T-cell epitopes responsible for the sacc-
141.
induced lymphoproliferative response is less clear, and awaits re-examination with
substrates whose composition is better-defined.
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Appendices
Appendix I: buffers and solutions
Carbonate-bicarbonate buffer, pH 9.6 : ELISA-plate coating buffer
0.05 M Na2C03 5.3 g/1 16 vols, (add to increase pH)
0.05 M NaHC03 4.2 g/1 34 vols, (add to decrease pH)
Mix in approximate proportions shown and titrate to pH 9.6
Phosphate-citrate buffer, pH 5: OPD buffer
0.1 M citric acid 21.01 g/1 1 vol. (add to decrease pH)
0.1 M Na2HP04 . 2H20 17.8 g/1 1 vol. (add to increase pH)
Mix in approximate proportions shown and titrate to pH 5
0.05% PBS-Tween: ELISA washing buffer
Add 5 ml Tween 20 (Sigma) to 10 1 PBS.
AET: preparation of SRBC
Dissolve 4.03 g AET in -905 ml water, titrate to pH 9 with 4 M NaOH and make up
to 100 ml
Erythrocyte lysing buffer
10 mM KHC03 0.2 g
150 mM NH4C1 1.6 g
0.14 mM EDTA 0.1 g
Make up to 200 ml in distilled water, adjust to pH 7.2, sterile filter and freeze
aliquots.
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Appendix II: titration of IL-2
The figure below shows the extent of proliferation supported by the
preparation of IL-2 alluded to in materials and methods. PBMC were cultured in
the presence of optimal concentrations of PHA or SK for 3 or 7 days, respectively,
after which they were washed and incubated in fresh medium with the concentrations
of IL-2 shown. The response of fresh PBMC is also shown. Thymidine uptake was








I i iii|—i—'—i i 111• |—i—i—i i 11111
medium .01 10 100
IL-2 (U/ml, final conc.)
162.
Appendix III: effectiveness of cell irradiation
The figure below shows the upake of tritiated thymidine by PHA-stimulated
PBMC on the third day after various periods of irradiation. In experimental work,
cells were invariably irradiated for 15-20 minutes.
irradiation time (min.)
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In vitro human lymphocyte proliferative responses to a
glycoprotein of the yeast Saccharomyces cerevisiae
C. J. DARROCH, S. E. CHRISTMAS & R. M. R. BARNES Department of Immunology, University of Liverpool
SUMMARY
Following reports of enhanced humoral immunity to Saccharomyces cerevisiae in patients with
Crohn's disease, and identification of an immunodominant, high molecular weight glycoprotein
(gp200), we have investigated the cellular immune response to this yeast in normal individuals.
Following exposure to a crude saline extract (Sacc), peripheral blood mononuclear cells (PBMC)
from these subjects demonstrated dose-dependent increases in tritiated thymidine incorporation, the
time-course of which resembled that of the response to the known recall antigens PPD and TT. This
was accompanied by increased cytotoxicity of the cultured cells for natural killer (NK)-sensitive and
NK-resistant target cell lines. Furthermore, using a purified, high molecular weight, glycoprotein
fraction of Sacc in culture, a dose-dependent lymphoproliferative response was again observed.
Stimulation indices (SI) for thymidine incorporation by umbilical cord blood lymphocytes exposed
to Sacc were low compared with those of normal adults. These results provide evidence for possible
antigen-specific, cellular, immune sensitization of normal individuals to a ubiquitous dietary
component.
INTRODUCTION
Recently, Main et al. using the enzyme-linked immunosorbent
assay (ELISA) technique with a crude saline extract of Sacchar¬
omyces cerevisiae as solid phase antigen, reported the presence
of specific IgG and IgA antibodies in the serum of patients with
Crohn's disease, and which distinguished this group from
normal controls and patients with ulcerative colitis.1 In the case
of antibodies of the IgG isotype, this observation held true for
11 of 12 S. cerevisiae strains examined, and there was no
serological cross-reactivity with two strains of Candida albi¬
cans.2 Results from this laboratory confirmed and extended
these findings, suggesting that IgA anti-Sacc antibody, though
less sensitive, was a more specific marker for Crohn's disease;3
furthermore, there was no correlation between the presence of
anti-Sacc antibodies and those reacting with Escherichia coli or
other dietary antigens. Sodium dodecyl sulphate-polyacryl-
amide gel electrophoresis (SDS-PAGE) followed by periodate
oxidation and immunoblotting with antibody-positive sera
suggest that the relevant antigen is a high molecular weight
(~ 200,000 MW), heat-stable, soluble glycoprotein (gp200).J
The demonstration of specific humoral immunity to this
putatively non-pathogenic organism, quantitatively different in
subjects with a specific pathology as compared with normal
individuals, raises the possibility that concomitant cellular
immunity to the same antigen is also present. The fact that in
vitro immune responses to the pathogenic fungus C. albicans
Received 22 April 1993; revised 21 June 1993; accepted 20 October
1993.
Correspondence: Dr C. J. Darroch. Dept. of Immunology, Univer¬
sity of Liverpool. PO Box 147. Liverpool L69 3BX. U.K.
have been extensively studied5 11 has provided a model for the
study of this related organism and we have previously reported
preliminary findings of increased in vitro DNA synthesis by
peripheral blood mononuclear cells (PBMC) in response to a
crude saline extract of the yeast (Sacc), which suggest that this is
the case even in normal subjects.
The aim of the present work has been to confirm and extend
these observations by making a qualitative comparison between
lymphocyte proliferative responses to Sacc and those to recog¬
nized recall antigens and mitogens, thereby establishing optimal
culture conditions with which to explore the phenomenon of
cell-mediated cytotoxicity induced by Sacc. The lymphoproli¬
ferative response to the previously identified high molecular
fraction of Sacc has also been examined.
MATERIALS AND METHODS
Preparation of cells
PBMC were obtained from normal subjects by the method of
Boyum.14 Briefly, aliquots of whole blood were collected from
donors by venepuncture and diluted with sterile, heparinized
(15 U/ml final concentration) physiological saline (ratio of
blood: saline = 1:1 to 2:1). This mixture was then separated on a
Lymphoprep (Nycomed, Oslo, Norway) density gradient by
centrifugation at 2000 rpm (~ 830g) for 20 min at 20°. The buffy
layer was removed by pipette and the cells washed once in an
excess of wash fluid [RPMI-1640/25 mM HEPES (Flow Labora¬
tories, Irvine, U.K.) plus heparin at 15 U/ml)] followed by
centrifugation at 1400 rpm (~400 g) for 15 min at 20 . After
discarding the supernatant, the pellets were resuspended in a
small volume ofcomplete culture medium [RPMI/HEPES, each
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100 ml supplemented with the following: 3 ml 7-5% NaHCO?
solution (Gibco, Paisley, U.K.); 10 ml heat-inactivated (56° for
30 min), sterile-filtered (0-2 pm), human AB serum; 2 ml l-
glutamine 200 mM (Gibco) and 2 ml of a solution containing
penicillin 5000 U/ml plus streptomycin 5000 pg/ml (Gibco)]
prior to counting. Cells obtained by this method were virtually
100% viable by trypan blue exclusion.
Heparinized umbilical cord blood was first depleted of
erythrocytes by preincubating each 10 ml aliquot with 2 ml 1%
methylcellulose (Sigma, St Louis) in phosphate-buffered saline
(PBS) at 37° for 15 min with mixing, then diluting with an equal
volume of physiological saline and allowing to settle for a
further 30 min prior to density gradient centrifugation of the
supernatant suspension with Lymphoprep.
Antigens and mitogens
Sacc. A saline extract of S. cerevisiae was prepared as
previously described.4 Briefly, 100 g of a commercially available
dried bakers' yeast (Sainsbury's) was suspended in 500 ml sterile
physiological saline at 4° and washed twice, resuspending to the
original volume after each centrifugation. Following the second
wash, the suspension was heated in a water-bath at 100° for
1 hr. After cooling, the suspension was centrifuged, and the
supernatant sterile filtered to 0-2 pm. Total protein concentra¬
tion was measured by the Coomassie brilliant blue colorimetric
method (Bio-Rad. Richmond, CA), and the preparation was
stored in aliquots at —20° until further use.
A purified high molecular weight fraction was prepared by
subjecting an aqueous extract (as above, but prepared in water
rather than saline) to an approximately sixfold volume reduc¬
tion by ultrafiltration using a TCF 2-micro-thin channel
ultrafiltration system (Amicon, Lexington, MA) with mem¬
branes having a 50,000 MW cut-off; the ultrafiltrate was then
lyophilized and that product was then applied to a Sepharose
CL6B column (Pharmacia, Uppsala, Sweden) equilibrated in
sterile water, and the fraction eluting in the void volume was
collected and lyophilized. This fraction showed a single band of
apparent MW = 200,000 after SDS-PAGE and staining with
Coomassie brilliant blue and periodic acid Schiff's reagent
(PAS).
Purified protein derivative of Mycobacterium tuberculosis
(PPDJ. A pharmaceutical preparation containing 100,000 U/
ml PPD (Evans Medical, Horsham, U.K.) was obtained. This
had a total protein concentration of 750 pg/m\ and was stored
until further use at 4°, according to the manufacturer's recom¬
mendations.
Tetanus toxoid (TT). Unadsorbed tetanus vaccine, 60 ml
(Evans Medical) was dialysed extensively against distilled water,
sterile filtered (0-2 pm), and lyophilized; it was then redissolved
to 10 ml in water, centrifuged, refiltered and stored at —20° until
further use.
Pokeweed mitogen (PWM). A stock solution was prepared
by dissolving 10 mg lyophilized mitogen (Sigma) in 5 mi sterile
water. Aliquots were stored at —20° until further use.
tnter/eukin-2 (IL-2). A stock solution of purified lympho-
blastoid IL-2 (Biotest. Dreieich, Germany) containing 100,000
U/ml was stored at 4°.
Proliferation assays
For dose-response and time-course experiments, PBMC were
adjusted to 2/3 x 106 lymphocytes/ml in culture medium and
plated on to sterile 96-well, U-bottomed culture plates (Flow) at
105 cells in 150 ^il/well. Dilutions of antigens/mitogens were
prepared in culture medium at four times their intended final
concentrations in culture and added to the wells in 50 p\
volumes; the same volume of culture medium alone was added
to control wells. Plates were then incubated for variable periods
at 37° in a humid atmosphere containing 5% C02.
On the day of harvesting, the cells were pulsed with [methyl-
3H]thymidine (1 mCi/ml) (Amersham International, Amer-
sham, U.K.) by adding 1 p\ to each well and incubating for a
further 6 hr. The cells were then harvested on to glass fibre filters
using a semi-automatic cell harvester (Flow). The filters were
allowed to dry overnight prior to /(-counting of the individual
discs in "OptiScint 'Hi Safe'" liquid scintillant (LKB, Surrey,
U.K.).
Medians were calculated for each group of replicate wells.
Results are expressed either as absolute c.p.m. or as the
stimulation index (SI: count for stimulated culture/count for
corresponding unstimulated control culture).
Cytotoxicity assay
Effector cells. PBMC were cultured in bulk at 5x10°
lymphocytes/ml in 50-ml flasks and under the same incubation
conditions as described above for the proliferative assay. Four
cultures were established for each donor, as follows: unstimu¬
lated cells; cells plus Sacc; cells plus PPD: cells plus IL-2. After 7
days, the cells were washed in RPMI supplemented with 10%
fetal calf serum (FCS), resuspended in a small volume of the
medium, and a viable count (trypan blue exclusion) performed.
Finally, the cells were adjusted to 5 x 105/ml.
Target cells. Two cell lines were used: mel-1, a natural killer
(NK)-resistant, malignant melanoma-derived cell: and Molt4.
an NK-sensitive, T-cell leukaemia-derived cell. These were
harvested from culture, washed twice in RPMI/FCS and the
centrifuged pellets were resuspended in the presence of 10/d of a
solution of 51Cr-sodium chromate (10 mCi/ml) (Flow). After
incubation for 1 hr at 37°, the cells were washed twice in RPMI/
FCS and adjusted to 5 x 104/ml after performing a viability
count.
The assay was performed by adding 150 ^1 of each effector
cell suspension to the same volume of each target cell suspension
in 11-mm diameter test-tubes in triplicate, to give an effector to
target cell ratio of 10:1. After gentle centrifugation at 1,000 rpm
(~ 208 g) for 5 min, followed by incubation for 4 hr at 37°, 150 pi
of supernatant was removed from each tube. Respective pairs of
pellets and supernatants were then counted in a y-counter.
Spontaneous release was calculated from tubes containing
target cells plus 150 fd medium only, and maximum release from
tubes containing target cells plus 150 pi 2% Triton 100 (BDH) to
lyse the cells. A mean background count was subtracted from
each experimental count, and the per cent cytotoxicity for each
pair of tubes calculated as follows:
% cytotoxicity = —^/p°"' x 100^max -**spont
where: RlesI = fractional release in test sample; /?spont = mean
spontaneous fractional release; Rmajl = mean maximum fractio¬
nal release. The mean of each triplicate was taken as the final
result.
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Figure 1. Dose-response relationship for: (a) Sacc; (b) PPD; (c) PWM.
In (a) and (b), eight replicate wells were used for each subject at each
dose, and six replicates in (c); the final response for each group of
replicates being the median of the individual counts. These medians
were then used to estimate the population median and the 95%
confidence interval (Wilcoxon) at that dose. Figures on the horizontal
axes refer to final concentrations in culture; cont. =control, medium
only added to culture. Arrows indicate concentrations used for the
subsequent time-course experiment.
Statistical analysis
Data were compared using the appropriate non-parametric tests




After 7 days in culture, the proliferation, as measured by
tritiated thymidine incorporation over 6 hr, of PBMC from
normal donors in response to a range of fourfold dilutions of
Sacc, PPD and PWM is shown in Fig. 1, where the median and
95% confidence interval for the sample is plotted at each
concentration. A major feature is that the demonstration of an
optimal response to Sacc appears to be more critically depen-
Days in culture
Figure 2. Time-course of response to: (a) Sacc (8-6 pg/ml); (b) PPD
(3-9 /rg/ml); (c) PWM (10 /rg/ml). Each experiment was performed on six
replicate wells and the analysis was as for the data in Fig. 1.
Mel1 Molt4
Figure 3. Cytotoxicity assay. Effector cells were obtained by culture of
lymphocytes from six normal donors: C = control (unstimulated) cells.
Concentrations of Sacc and PPD used for preculture of effector cells
were as for Fig. 2; IL-2 was used at 50 U/ml. Bars show mean + SEM %
cytotoxicity by effector cells, incubated in a ratio of 10: 1 with target
cells.
250 C. J. Darroch, S. E. Christmas & R. M. R. Barries
103 :
(a)





















-I 1 1 1 1 1 1 1
cont. 098 3-9 16




Figure 4. Proliferative response to purified Sacc. Cells were harvested on
3 consecutive days: (a) day 6: (b) day 7; (c) day 8. Each data point is the
median of five replicates. Separate dose-response curves are shown for
each of the four subjects.
dent on dose than is the case for PPD and PWM, which both
produce a shallow plateau of responses over a greater than 200-
fold concentration range.
Data on the time-course of the proliferative responses (Fig.
2) were obtained by measuring tritiated thymidine incorpora¬
tion daily in the presence of that concentration of Sacc, PPD and
PWM which had produced the optimal response at 7 days (these
are indicated by arrows against the horizontal axes in Fig. 1).
Whereas PWM elicited very early proliferation which was






Sacc PPD TT PWM
Figure 5. Comparison of proliferative responses of PBMC (□, n- 4) and
CBMC (0. n = 9), expressed as: (a) absolute c.p.m.: (b) SI. Bars show
mean + SEM derived from five replicates.
responses to Sacc and PPD were delayed at 7 days and 5-6 days
respectively.
The dose dependency and time-course of the response to TT
(not shown) closely resembled that of PPD.
Cytotoxicity
The per cent cytotoxicity obtained against the mel-1 and Molt4
cell lines with an effector to target cell ratio of 10:1 is shown in
Fig. 3. Similar results were obtained for ratios of 20:1 and 5:1
(data not shown). All effector cell samples demonstrated
cytotoxicity significantly greater than that of the unstimulated
control at P<0-05 (Wilcoxon signed rank test). Antigen-
stimulated cells elicited greater killing against the NIC-sensitive
line (Molt4) compared with the NIC-resistant line (mel-1).
Proliferative responses to purified Sacc
PBMC were obtained from four donors who had previously
demonstrated significant proliferative responses to Sacc and
tested for their ability to proliferate in response to doubling
dilutions of a high molecular weight fraction purified by gel
filtration. Figure 4 shows that the responses were comparable
regardless of whether cells were harvested after 6. 7 or 8 days in
culture. Furthermore, it can be seen that the amount of
thymidine incorporation is less critically dependent on dose
than was the case for the unfractionated Sacc preparation, and
in this respect the response more closely resembles those of PPD
and TT.
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Proliferative response of cord blood lymphocytes
Cord blood mononuclear cells (CBMC) were incubated with
concentrations of Sacc, PPD, TT and PWM which had been
shown to be optimal for adult PBMC. After 7 days in culture,
the incorporation of tritiated thymidine was compared with that
of similar cultures of normal adult PBMC (Fig. 5). Although the
responses, in absolute c.p.m. of stimulated CBMC cultures were
in each case not significantly different from those of PBMC (Fig.
5a), unstimulated CBMC cultures uniformly demonstrated a
high background uptake [P<0-01 (Mann-Whitney) cf. PBMC]
with consequently reduced SI for stimulated cultures [P<0-01
(Mann-Whitney) cf. PBMC] (Fig. 5b).
DISCUSSION
Saccharomyces cerevisiae is not recognized as a pathogen except
in rare, anecdotal cases. However, exposure to this organism in
the form of bakers'/brewers' yeast is virtually universal and the
demonstration of humoral immunity to the yeast extract Sacc,
specifically in relation to Crohn's disease,1 4 raises the possibility
of sensitization via the gut-associated lymphoid tissue (GALT),
a site at which activated T lymphocytes may be involved in
induction or maintainance of gastrointestinal disease.15
Using incorporation of tritiated thymidine as a marker of
DNA synthesis in PBMC, it has been possible to establish dose-
response relationships for Sacc, PPD and PWM after 7 days in
culture (Fig. 1). Although the profile of the Sacc response
appears to differ markedly from those of PPD and PWM, in so
far as optimal thymidine uptake is more critically dependent on
a narrow range of concentrations, this may have been an
artefact due to the nature of the preparation used: that is, above
a concentration of total Sacc protein of 17 pgjm\ it may not have
been possible to increase the proportion of the saline extract in
the culture medium without either introducing significant
amounts of inhibitory factors or excessively diluting essential
components of the medium. Indeed, this anomaly was not
observed with the purified, lyophilized, high molecular fraction
(see below).
Having thus established appropriate optimal concentra¬
tions, the time-course of each response was examined (Fig. 2).
The kinetics of the responses to Sacc and PPD are similar and
contrast with that to PWM in that the maximum responses are
delayed, reaching well-defined peaks on day 7 (Sacc) and day 6
(PPD), compared with the early plateau of thymidine uptake
seen with PWM. It could be argued that this observation
supports the suggestion that Sacc, like PPD. is mediating
lymphocyte activation in an antigen-dependent manner rather
than acting non-specifically as a mitogen. This conclusion might
be criticized on the grounds that a maximal response at about 7
days has already been preselected on the basis of the doses
chosen and that the earlier response to PWM merely reflects less
stringent dose requirements rather than a fundamental differ¬
ence in the kinetics of the response per se. However, when
tetanus toxoid was used as recall antigen, it also resulted in
maximum uptake at 5-7 days, and this remained true over a
greater than 200-fold dose range (results not shown). The
kinetics of the response to Sacc are in broad agreement with
those reported elsewhere for antigenic preparations of C.
albicansA6
In previous studies in mouse and man. C. albicans-stimu¬
lated cells have been shown to possess in vitro cytotoxic activity
against a variety of allogeneic targets and this has been
attributed to induction of NK cell activity.7 9 Sacc also appears
to have this property: the cytotoxicity of Sacc-stimulatcd cells
for both NK-sensitive and NK-resistant cell lines was statisti¬
cally greater than that demonstrated by negative control cells
(Fig. 3). The levels of cytotoxic activity induced by Sacc were
less than those obtained with the control antigen PPD, and this
may reflect differences in the precursor frequency or phenotype
of lymphocyte subsets which each activates. In the studies on C.
albicans cited, cytotoxicity was also greater, and although the
different target cell lines, and in some cases, higher effector: tar¬
get cell ratios used in those experiments make direct comparison
with the current data difficult, Sacc does appear to be a less
potent inducer of cytotoxicity than C. albicans.
The ability of a purified high molecular weight glycoprotein
fraction of Sacc to elicit a lymphoproliferative response was
examined, and, as is shown in Fig. 4, this retained similar
efficacy to the crude preparation. This fraction had the electro-
phoretic and staining characteristics of the previously identified
gp200,4 properties also shared by a heat-stable mannoprotein
fraction of C. albicans which was recognized by anti-Candida
rabbit serum and has been demonstrated to induce lymphopro-
liferation and cytotoxicity in vitro 9
Umbilical cord blood contains T cells which are said to be
phenotypically and functionally immature.16 In some studies, in
vitro CBMC responsiveness to a stimulating substance, for
example, mannan of C. albicans," has been taken to imply
mitogenicity. However, weak CBMC responses to antigenic
stimuli are detectable, and. in the case of food antigens, have
been proposed as predictors of future allergy.18 In addition,
limiting dilution analysis has demonstrated a precursor fre¬
quency of PPD-specific cells in cord blood only 10- to 100-fold
less than adult peripheral blood, and no difference in the
frequencies of cells from these populations which respond to the
65,000 MW mycobacterial heat-shock protein.19 Because cell
preparations may differ in their spontaneous rate of thymidine
uptake, the SI is often used as a device to normalize data from
lymphoproliferation assays; we, and others,16 have found
CBMC to generate particularly high background counts.
Although results manipulated in this way should be interpreted
with caution, our experiments showed CBMC responses to
Sacc, PPD and TT which, expressed as SI, were significantly less
than those of PBMC, whereas there was no difference between
cell populations when results were expressed in c.p.m. Micro¬
scopic visual inspection of the cultures tended to support the
conclusion that significant proliferation of CBMC only
occurred in response to PWM; in this latter instance, the
apparently low SI may have been due to the fact that it was
measured after the peak response had been achieved.
In conclusion, in keeping with the apparent ability of 5.
cerevisiae to elicit humoral immune responses in man in vivo.
soluble preparations of the organism can induce a lymphoproli¬
ferative response in vitro which is kinetically similar to that due
to known recall antigens. This property is retained by a high
molecular weight fraction and is accompanied by the ability to
induce cytotoxic activity in stimulated cells. Whether the
response of PBMC to Sacc is truly antigen specific remains to be
established, as the evidence presented here, based on the kinetics
of the response and hyporesponsiveness of CBMC, is merely
suggestive. However, it has been shown (C. J. Darroch. S. E.
Christmas and R. M. R. Barnes, unpublished observations) that
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randomly selected T-cell clones, which proliferate in response to
PWM and phytohaemmagglutinin, are not stimulated by Sacc,
and work is in progress to attempt to isolate clones which are
specifically responsive to Sacc.
Although the biochemical nature of the active component(s)
of Sacc has not been fully characterized, the method of
preparation, possession of electrophoretic and staining charac¬
teristics ofa high molecular weight glycoprotein, and the known
immunological properties of yeasts10 " make cell wall mannan
the most likely candidate (preliminary analysis of the purified
preparation supports this suggestion).
It is not known what relevance the ubiquitous presence of S.
cerevisiae in food has to these observations. Lymphoprolifera-
tive responses to other food antigens are not universally
demonstrable in normal individuals;20 Sacc may be unusual in
this respect, and further study is necessary to characterize its role
in health and disease.
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